株探米国株
日本語 英語
エドガーで原本を確認する
0001099219false00010992192024-05-012024-05-010001099219us-gaap:CommonStockMember2024-05-012024-05-010001099219us-gaap:SeriesAPreferredStockMember2024-05-012024-05-010001099219us-gaap:SeriesEPreferredStockMember2024-05-012024-05-010001099219us-gaap:SeriesFPreferredStockMember2024-05-012024-05-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549  
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 1, 2024
METLIFE, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
 
1-15787 13-4075851
(Commission File Number) (IRS Employer Identification No.)
200 Park Avenue, New York, NY 10166-0188
(Address of Principal Executive Offices) (Zip Code)
(212) 578-9500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 MET New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock,
Series A, par value $0.01
MET PRA New York Stock Exchange
Depositary Shares, each representing a 1/1,000th
interest in a share of 5.625% Non-Cumulative
Preferred Stock, Series E
MET PRE New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F MET PRF
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐



Item 2.02 Results of Operations and Financial Condition.
On May 1, 2024, MetLife, Inc. issued (i) a news release announcing its results for the quarter ended March 31, 2024 (the “Earnings Release”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, (ii) a Quarterly Financial Supplement for the quarter ended March 31, 2024 (the “Quarterly Financial Supplement”), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference and (iii) a fact sheet setting forth its total assets under management as of March 31, 2024 (the "Total AUM Fact Sheet"), a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.
The Earnings Release and the Quarterly Financial Supplement are furnished and not filed pursuant to instruction B.2 of Form 8-K. The foregoing description of the Total AUM Fact Sheet is not complete and is qualified in its entirety by reference to the Total AUM Fact Sheet, which is filed as Exhibit 99.3.
Item 7.01 Regulation FD Disclosure.
On May 1, 2024, MetLife, Inc. issued a supplemental slide presentation for the quarter ended March 31, 2024, (the “Supplemental Slides”), a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference. The slides highlight information in MetLife, Inc.’s Earnings Release and Quarterly Financial Supplement, as well as other prior public disclosures. The Supplemental Slides are furnished and not filed pursuant to instruction B.2 of Form 8-K.
Item 8.01 Other Events.
On May 1, 2024, MetLife, Inc. announced that its Board of Directors approved a new $3 billion authorization to repurchase its common stock.
The text of Item 2.02 above with respect to the Total AUM Fact Sheet is incorporated herein by reference.
2


Item 9.01 Financial Statements and Exhibits.

101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language)
104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)
3


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
METLIFE, INC.
By: /s/ Tamara L. Schock
Name: Tamara L. Schock
Title: Executive Vice President and
Chief Accounting Officer
Date: May 1, 2024
4
EX-99.1 2 ex991earningsreleasetables.htm EX-99.1 Document

Exhibit 99.1

mllogonewa22a.jpg
                    For Immediate Release İ Global Communications İ MetLife, Inc.


METLIFE ANNOUNCES FIRST QUARTER 2024 RESULTS
NEW YORK, May 1, 2024 - MetLife, Inc. (NYSE: MET) today announced its first quarter 2024 results.
First Quarter Results Summary
•Net income of $800 million, or $1.10 per share, compared to net income of $14 million, or $0.02 per share, in the first quarter of 2023.
•Adjusted earnings of $1.3 billion, or $1.83 per share, compared to adjusted earnings of $1.2 billion, or $1.52 per share, in the first quarter of 2023.
•Book value of $34.54 per share, down 6 percent from $36.89 per share at March 31, 2023.
•Book value, excluding accumulated other comprehensive income (AOCI) other than foreign currency translation adjustments (FCTA), of $53.13 per share, down 1 percent from $53.83 per share at March 31, 2023.
•Return on equity (ROE) of 12.6 percent.
•Adjusted ROE, excluding AOCI other than FCTA, of 13.8 percent.
•Holding company cash and liquid assets of $5.2 billion at March 31, 2024, which is above the target cash buffer of $3.0 - $4.0 billion.


“MetLife is off to a good start in 2024, with strong topline growth and sustained momentum across our market-leading portfolio of businesses,” said MetLife President and CEO Michel Khalaf. “The progress we have made through the consistent execution of our strategy positions us to drive further growth, creating long-term value for our shareholders and other stakeholders.”










Page 1 of 24




First Quarter 2024 Summary
($ in millions, except per share data)
Three Months Ended
March 31,
2024 2023 Change
Premiums, fees and other revenues $ 11,975 $ 11,517 4%
Net investment income
5,436 4,645 17%
Net investment gains (losses)
(375) (684)
Net derivative gains (losses)
(979) (90)
Total revenues
$ 16,057 $ 15,388
Adjusted premiums, fees and other revenues
$ 11,948 $ 11,520 4%
Adjusted premiums, fees and other revenues, excluding pension risk transfers (PRT) $ 11,973 $ 11,541 4%
Market risk benefit remeasurement gains (losses) $ 694 $ (188)
Net income (loss)
$ 800 $ 14 NM*
Net income (loss) per share
$ 1.10 $ 0.02 NM*
Adjusted earnings
$ 1,334 $ 1,184 13%
Adjusted earnings per share
$ 1.83 $ 1.52 20%
Adjusted earnings, excluding total notable items
$ 1,334 $ 1,184 13%
Adjusted earnings, excluding total notable items per share
$ 1.83 $ 1.52 20%
Book value per share
$ 34.54 $ 36.89 (6)%
Book value per share, excluding AOCI other than FCTA
$ 53.13 $ 53.83 (1)%
Expense ratio
20.5  % 20.3  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT
11.9  % 12.0  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 20.4  % 20.0  %
ROE
12.6  % 0.2  %
Adjusted ROE, excluding AOCI other than FCTA
13.8  % 11.3  %
Adjusted ROE, excluding total notable items (excludes AOCI other than FCTA)
13.8  % 11.3  %
*Not meaningful. For more information, refer to "Non-GAAP and Other Financial Disclosures."
Information regarding the non-GAAP and other financial measures included in this news release and reconciliation of the non-GAAP financial measures to GAAP measures are in “Non-GAAP and Other Financial Disclosures” below and in the tables that accompany this news release.
Supplemental slides for the first quarter of 2024, titled “1Q24 Supplemental Slides” are available on the MetLife Investor Relations website at https://investor.metlife.com and in the Form 8-K furnished by MetLife to the U.S. Securities and Exchange Commission in connection with this earnings release. Supplemental information about MetLife's diversified global investment portfolio is contained in the "1Q24 - General Account Assets Under Management Fact Sheet," available on the above-mentioned website.
Page 2 of 24



Total Company Discussion
MetLife reported first quarter 2024 premiums, fees and other revenues of $12.0 billion, up 4 percent compared to the first quarter of 2023. Adjusted premiums, fees and other revenues were $11.9 billion, also up 4 percent on a reported basis and up 5 percent on a constant currency basis from the prior-year period.
Net investment income was $5.4 billion, up 17 percent from the first quarter of 2023, driven by higher variable investment income, higher interest rates and increases in the estimated fair value of certain securities that do not qualify as separate accounts under GAAP. Adjusted net investment income was $5.1 billion, up 10 percent from the prior-year period, largely driven by higher variable investment income and higher interest rates.
Net investment losses were $375 million, or $296 million after tax during the quarter primarily driven by normal trading activity in the portfolio. Net derivative losses amounted to $979 million, or $773 million after tax during the quarter, largely driven by the U.S. dollar strengthening, higher equity markets and an increase in long-term interest rates.
Net income was $800 million, compared to net income of $14 million in the first quarter of 2023. The gain in net income from the prior-year period was driven by higher adjusted earnings and lower net investment losses. On a per-share basis, net income was $1.10, compared to net income of $0.02 in the prior-year period.
MetLife reported adjusted earnings of $1.3 billion, up 13 percent on both a reported and a constant currency basis, from the first quarter of 2023. On a per-share basis, adjusted earnings were $1.83, up 20 percent from the prior-year period.

Adjusted Earnings by Segment Summary*
Three Months Ended
March 31, 2024
Segment Change from
prior-year period
Change from
prior-year period
(on a constant
currency basis)
Group Benefits (7)%
Retirement and Income Solutions (RIS) —%
Asia 51% 57%
Latin America 8% 5%
Europe, the Middle East and Africa (EMEA)
28% 35%
MetLife Holdings 1%
*The percentages in this table are on a reported and constant currency basis.

Business Discussions
All comparisons of the results for the first quarter of 2024 in the business discussions that follow are with the first quarter of 2023, unless otherwise noted. There were no notable items in the first quarter of 2024, as indicated in the notable items table which follows the Business Discussions section of this release.

Page 3 of 24




GROUP BENEFITS
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings
$284 $307 (7)%
Adjusted premiums, fees and other revenues
$6,330 $6,049 5%
Notable item(s) $0 $0

•Adjusted earnings were $284 million, down 7 percent, driven primarily by lower non-medical health underwriting margins.
•Adjusted premiums, fees and other revenues were $6.3 billion, up 5 percent, driven by solid growth across core and voluntary products.
•Sales were up 25 percent, driven by strong growth across both core and voluntary products.



RIS
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings
$399 $400 —%
Adjusted premiums, fees and other revenues
$813 $648 25%
Adjusted premiums, fees and other revenues, excluding PRT
$838 $669 25%
Notable item(s) $0 $0  

•Adjusted earnings were $399 million, essentially flat, compared to the prior-year period. Higher variable investment income was offset by lower recurring interest margins and less favorable underwriting.
•Adjusted premiums, fees and other revenues were $813 million, compared to $648 million in the prior-year period, largely driven by structured settlement sales and growth in UK longevity reinsurance.
•Sales were up 49 percent, driven by structured settlement sales and corporate-owned life insurance products.










Page 4 of 24



ASIA
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings $423 $280 51%
Adjusted earnings (constant currency)
$423 $269 57%
Adjusted premiums, fees and other revenues
$1,744 $1,794 (3)%
Notable item(s) $0 $0
Asia general account assets under management (at amortized cost) $128,618 $127,120 1%

•Adjusted earnings were $423 million, up 51 percent on a reported basis, and up 57 percent on a constant currency basis, driven by higher variable investment income and favorable underwriting, and favorable tax benefits.
•Adjusted premiums, fees and other revenues were $1.7 billion, down 3 percent on a reported basis, and up 5 percent on a constant currency basis.
•Asia general account assets under management (at amortized cost) were $128.6 billion, up 1 percent on a reported basis, and up 6 percent on a constant currency basis.
•Sales were $584 million, down 8 percent on a constant currency basis primarily due to strong sales in the prior-year period.



LATIN AMERICA
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings $233 $215 8%
Adjusted earnings (constant currency)
$233 $221 5%
Adjusted premiums, fees and other revenues
$1,496 $1,372 9%
Notable item(s) $0 $0

•Adjusted earnings were $233 million, up 8 percent on a reported basis, and up 5 percent on a constant currency basis, driven by higher Chilean encaje returns, volume growth and favorable underwriting.
•Adjusted premiums, fees and other revenues were $1.5 billion, up 9 percent on a reported basis, and up 8 percent on a constant currency basis, driven by strong sales and solid persistency across the region.
•Sales were $411 million, flat to the prior-year period on a constant currency basis, with strong sales in both quarters.



Page 5 of 24




EMEA
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings
$77 $60 28%
Adjusted earnings (constant currency)
$77 $57 35%
Adjusted premiums, fees and other revenues
$620 $581 7%
Notable item(s)
$0 $0

•Adjusted earnings were $77 million, up 28 percent on a reported basis and up 35 percent on a constant currency basis, driven by favorable underwriting, volume growth and higher recurring interest margins, partially offset by higher expenses.
•Adjusted premiums, fees and other revenues were $620 million, up 7 percent on a reported basis and up 9 percent on a constant currency basis due to strong sales across the region.
•Sales were $292 million, up 16 percent on a constant currency basis.

METLIFE HOLDINGS
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings
$159 $158 1%
Adjusted premiums, fees and other revenues
$841 $959 (12)%
Notable item(s)
$0 $0

•Adjusted earnings were $159 million, up 1 percent, driven by higher variable investment income, offset by foregone earnings as a result of the reinsurance transaction that became effective in November.
•Adjusted premiums, fees and other revenues were $841 million, down 12 percent.


CORPORATE & OTHER
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted earnings $(241) $(236)
Notable item(s) $0 $0

•Adjusted loss of $241 million, compared to an adjusted loss of $236 million in the prior-year period.




Page 6 of 24




INVESTMENTS
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Adjusted net investment income
$5,068 $4,606 10%

•Adjusted net investment income was $5.1 billion, up 10 percent. Recurring investment income was $4.8 billion, compared with $4.7 billion in the prior-year period, driven by higher interest rates. Variable investment income was $260 million, compared to variable investment loss of $44 million in the prior-year period, driven by higher private equity returns.

FIRST QUARTER 2024 NOTABLE ITEMS
($ in millions)
Adjusted Earnings
Three Months Ended March 31, 2024
Notable Items Group Benefits RIS Asia Latin
America
EMEA MetLife
Holdings
Corporate
&
Other
Total
Total notable items $0 $0 $0 $0 $0 $0 $0 $0

###


Contacts:     For Media:     Dave Franecki (973) 264-7465, Dave.Franecki@metlife.com    
For Investors:      John Hall (212) 578-7888, John.A.Hall@metlife.com

About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.
Conference Call
MetLife will hold its first quarter 2024 earnings conference call and audio webcast on Thursday, May 2, 2024, from 9-10 a.m. (ET). The conference call will be available live via telephone and the internet. To listen via telephone, dial 877-692-8955 (U.S.) or 234-720-6979 (outside the U.S.). The participant access code is 2510803. To listen to the conference call via the internet, click the link to the webcast on the MetLife Investor Relations web page (https://investor.metlife.com). Those who want to listen to the call via telephone or the internet should dial in or go to the website at least 15 minutes prior to the call to register, and/or download and install any necessary audio software.

The conference call will be available for replay via telephone and the internet beginning at 11
Page 7 of 24



a.m. (ET) on Thursday, May 2, 2024, until Thursday, May 9, 2024, at 11:59 p.m. (ET). To listen to a replay of the conference call via telephone, dial 866-207-1041 (U.S.) or 402-970-0847 (outside the U.S.). The access code for the replay is 4857872. To access the replay of the conference call over the internet, visit the above-mentioned website.


Non-GAAP and Other Financial Disclosures
Any references in this news release (except in this section and the tables that accompany this release) to: should be read as, respectively:
(i) net income (loss); (i)  net income (loss) available to MetLife, Inc.’s common shareholders;
(ii) net income (loss) per share; (ii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(iii) adjusted earnings; (iii) adjusted earnings available to common shareholders;
(iv) adjusted earnings per share; (iv) adjusted earnings available to common shareholders per diluted common share;
(v) book value per share; (v) book value per common share;
(vi) book value per share, excluding AOCI other than FCTA; (vi) book value per common share, excluding AOCI other than FCTA;
(vii) return on equity; and (vii) return on MetLife, Inc.’s common stockholders’ equity; and
(viii) adjusted return on equity, excluding AOCI other than FCTA. (viii) adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA.
In this news release, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures: Comparable GAAP financial measures:
(i) total adjusted revenues; (i) total revenues;
(ii) total adjusted expenses; (ii) total expenses;
(iii) adjusted premiums, fees and other revenues; (iii) premiums, fees and other revenues;
(iv) adjusted premiums, fees and other revenues, excluding PRT; (iv) premiums, fees and other revenues;
(v) adjusted net investment income; (v) net investment income;
(vi) adjusted capitalization of deferred policy acquisition costs (DAC); (vi) capitalization of DAC;
Page 8 of 24



(vii) adjusted earnings available to common shareholders; (vii) net income (loss) available to MetLife, Inc.’s common shareholders;
(viii) adjusted earnings available to common shareholders, excluding total notable items; (viii) net income (loss) available to MetLife, Inc.’s common shareholders;
(ix) adjusted earnings available to common shareholders per diluted common share; (ix) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(x) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share; (x) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share;
(xi) adjusted return on equity; (xi) return on equity;
(xii) adjusted return on equity, excluding AOCI other than FCTA; (xii) return on equity;
(xiii) adjusted return on equity, excluding total notable items (excludes AOCI other than FCTA); (xiii) return on equity;
(xiv) investment portfolio gains (losses); (xiv) net investment gains (losses);
(xv) derivative gains (losses); (xv) net derivative gains (losses);
(xvi) total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA; (xvi) total MetLife, Inc.’s stockholders’ equity;
(xvii) total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA); (xvii) total MetLife, Inc.’s stockholders’ equity;
(xviii) book value per common share, excluding AOCI other than FCTA; (xviii) book value per common share;
(xix) free cash flow of all holding companies; (xix) MetLife, Inc. (parent company only) net cash provided by (used in) operating activities;
(xx) adjusted other expenses; (xx) other expenses;
(xxi) adjusted other expenses, net of adjusted capitalization of DAC; (xxi) other expenses, net of capitalization of DAC;
(xxii) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses; (xxii) other expenses, net of capitalization of DAC;
(xxiii) adjusted expense ratio; (xxiii) expense ratio;
(xxiv) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT; (xxiv) expense ratio;
(xxv) direct expenses; (xxv) other expenses;
(xxvi) direct expenses, excluding total notable items related to direct expenses; (xxvi) other expenses;
(xxvii) direct expense ratio; and (xxvii) expense ratio; and
(xxviii) direct expense ratio, excluding total notable items related to direct expenses and PRT. (xxviii) expense ratio.

Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period.
Page 9 of 24



As a result, comparable prior period amounts are updated each period to reflect the most recent period average foreign currency exchange rates.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings news release and in this period’s quarterly financial supplement, which is available at www.metlife.com.
MetLife’s definitions of non-GAAP and other financial measures discussed in this news release may differ from those used by other companies:
Adjusted earnings and related measures
•adjusted earnings;
•adjusted earnings available to common shareholders;
•adjusted earnings available to common shareholders on a constant currency basis;
•adjusted earnings available to common shareholders, excluding total notable items;
•adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis;
•adjusted earnings available to common shareholders per diluted common share;
•adjusted earnings available to common shareholders on a constant currency basis per diluted common share;
•adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
•adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis per diluted common share.
These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.
Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.
Adjusted revenues and adjusted expenses
These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.
Market volatility can have a significant impact on MetLife’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
•Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
Page 10 of 24



•Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.
•Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
•Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.
Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.
Other adjustments are made to the line items indicated in calculating adjusted earnings:
•Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs").
•Other revenues include fee revenue on synthetic guaranteed interest contracts ("GICs") accounted for as freestanding derivatives.
•Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
•Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.
In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.

Investment portfolio gains (losses) and derivative gains (losses)
These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).
Page 11 of 24



Return on equity and related measures
•Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.
•Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, and total notable items, net of income tax.
•Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.’s average common stockholders’ equity.
•Adjusted return on MetLife, Inc.'s common stockholders' equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders' equity.
•Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders' equity, excluding AOCI other than FCTA.
•Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA).
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, MetLife does not plan to sell most investments for the sole purpose of realizing gains or losses.
Expense ratio, direct expense ratio, adjusted expense ratio and related measures
•Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
•Direct expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses.
•Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
•Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
•Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Asia General account (GA) assets under management (GA AUM) and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.
Page 12 of 24



Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.
Statistical sales information:
•Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products.
•RIS: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance.
•Latin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group).
Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
The following additional information is relevant to an understanding of MetLife’s performance results and outlook:
•Volume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates.
•Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.
•MetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders.
•Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders.
•We refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.
Page 13 of 24



•Not Meaningful (NM) indicates a percentage change in a financial metric over a specified period of time and reflects changes in factors that are subject to volatility, and should not, accordingly be viewed as representative of a reasonable trend currently or in the future. For example,
($ in millions) Three Months Ended
March 31, 2024
Three Months Ended
March 31, 2023
Change
Net income (loss) $800 $14 5,614%
Net income (loss) per share $1.10 $0.02 5,400%

Forward-Looking Statements
This news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” "are confident," “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would,” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.

Many factors determine the results of MetLife, Inc., its subsidiaries and affiliates, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. MetLife, Inc. does not guarantee any future performance. Our results could differ materially from those MetLife, Inc. expresses or implies in forward-looking statements. The risks, uncertainties and other factors identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:

(1)economic condition difficulties, including risks relating to interest rates, credit spreads, declining equity or debt markets, real estate, obligors and counterparties, government default, currency exchange rates, derivatives, climate change, public health and terrorism and security;
(2)global capital and credit market adversity;
(3)credit facility inaccessibility;
(4)financial strength or credit ratings downgrades;
(5)unavailability, unaffordability, or inadequate reinsurance, including reinsurance risks that arise from reinsurers' credit risk, and the potential shortfall or failure of risk mitigants to protect against such risks;
(6)statutory life insurance reserve financing costs or limited market capacity;
(7)legal, regulatory, and supervisory and enforcement policy changes;
(8)changes in tax rates, tax laws or interpretations;
(9)litigation and regulatory investigations;
(10)unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;
(11)MetLife, Inc.’s inability to pay dividends and repurchase common stock;
(12)MetLife, Inc.’s subsidiaries’ inability to pay dividends to MetLife, Inc.;
(13)investment defaults, downgrades, or volatility;
(14)investment sales or lending difficulties;
(15)collateral or derivative-related payments;
(16)investment valuations, allowances, or impairments changes;
(17)claims or other results that differ from our estimates, assumptions, or models;
Page 14 of 24



(18)global political, legal, or operational risks;
(19)business competition;
(20)technological changes;
(21)catastrophes;
(22)climate changes or responses to it;
(23)deficiencies in our closed block;
(24)goodwill or other asset impairment, or deferred income tax asset allowance;
(25)impairment of VOBA, value of distribution agreements acquired or value of customer relationships acquired;
(26)product guarantee volatility, costs, and counterparty risks;
(27)risk management failures;
(28)insufficient protection from operational risks;
(29)failure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;
(30)accounting standards changes;
(31)excessive risk-taking;
(32)marketing and distribution difficulties;
(33)pension and other postretirement benefit assumption changes;
(34)inability to protect our intellectual property or avoid infringement claims;
(35)acquisition, integration, growth, disposition, or reorganization difficulties;
(36)Brighthouse Financial, Inc. separation risks;
(37)MetLife, Inc.’s Board of Directors influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and
(38)legal- and corporate governance-related effects on business combinations.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

Page 15 of 24



MetLife, Inc.
GAAP Interim Condensed Consolidated Statements of Operations
(In millions)
For the Three Months Ended
March 31,
2024 2023
Revenues
Premiums $ 10,053  $ 9,589 
Universal life and investment-type product policy fees 1,248  1,289 
Net investment income 5,436  4,645 
Other revenues 674  639 
Net investment gains (losses) (375) (684)
Net derivative gains (losses) (979) (90)
Total revenues 16,057  15,388 
Expenses
Policyholder benefits and claims 10,074  9,872 
Policyholder liability remeasurement (gains) losses (22) (9)
Market risk benefit remeasurement (gains) losses (694) 188 
Interest credited to policyholder account balances 2,290  1,864 
Policyholder dividends 147  159 
Amortization of DAC and VOBA 508  470 
Amortization of negative VOBA (6) (7)
Interest expense on debt 264  255 
Other expenses, net of capitalization of DAC 2,451  2,339 
Total expenses 15,012  15,131 
Income (loss) before provision for income tax 1,045  257 
Provision for income tax expense (benefit) 170  172 
Net income (loss) 875  85 
Less: Net income (loss) attributable to noncontrolling interests
Net income (loss) attributable to MetLife, Inc. 867  80 
Less: Preferred stock dividends 67  66 
Net income (loss) available to MetLife, Inc.'s common shareholders $ 800  $ 14 
See footnotes on last page.
Page 16 of 24



MetLife, Inc.
(In millions, except per share data)
For the Three Months Ended
March 31,
2024 2023
Reconciliation to Adjusted Earnings Available to Common Shareholders Earnings Per
Weighted Average
Common Share Diluted (1)
Earnings Per
Weighted Average
Common Share Diluted (1)
Net income (loss) available to MetLife, Inc.'s common shareholders $ 800  $ 1.10  $ 14  $ 0.02 
Adjustments from net income (loss) available to common shareholders to adjusted earnings available to common shareholders:
Less: Net investment gains (losses) (375) (0.51) (684) (0.88)
Net derivative gains (losses) (979) (1.34) (90) (0.12)
Market risk benefit remeasurement gains (losses) 694  0.95  (188) (0.24)
Premiums —  —  —  — 
Universal life and investment-type product policy fees —  —  —  — 
Net investment income 368  0.51  39  0.05 
Other revenues 27  0.04  (3) — 
Policyholder benefits and claims and policyholder dividends 53  0.07  (70) (0.09)
Policyholder liability remeasurement (gains) losses —  —  —  — 
Interest credited to policyholder account balances (563) (0.78) (322) (0.41)
Capitalization of DAC —  —  —  — 
Amortization of DAC and VOBA —  —  —  — 
Amortization of negative VOBA —  —  —  — 
Interest expense on debt —  —  —  — 
Other expenses (11) (0.02) (27) (0.03)
Goodwill impairment —  —  —  — 
Provision for income tax (expense) benefit 260  0.36  180  0.23 
Add: Net income (loss) attributable to noncontrolling interests 0.01  0.01 
Preferred stock redemption premium —  —  —  — 
Adjusted earnings available to common shareholders 1,334  1.83  1,184  1.52 
Less: Total notable items (2) —  —  —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 1,334  $ 1.83  $ 1,184  $ 1.52 
Adjusted earnings available to common shareholders on a constant currency basis $ 1,334  $ 1.83  $ 1,176  $ 1.51 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 1,334  $ 1.83  $ 1,176  $ 1.51 
Weighted average common shares outstanding - diluted 728.4  781.2 
See footnotes on last page.
Page 17 of 24



MetLife, Inc.
(In millions)
 For the Three Months Ended
March 31,
2024 2023
Premiums, Fees and Other Revenues
Premiums, fees and other revenues $ 11,975  $ 11,517 
Less: Adjustments to premiums, fees and other revenues:
Asymmetrical and non-economic accounting 39  — 
Other adjustments (12) (3)
Divested businesses —  — 
Adjusted premiums, fees and other revenues $ 11,948  $ 11,520 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 11,948  $ 11,380 
Less: PRT (25) (21)
Adjusted premiums, fees and other revenues, excluding PRT, on a constant currency basis $ 11,973  $ 11,401 
Net Investment Income
Net investment income $ 5,436  $ 4,645 
Less: Adjustments to net investment income
Investment hedge adjustments (176) (264)
Unit-linked contract income 542  303 
Other adjustments — 
Divested businesses —  — 
Adjusted net investment income $ 5,068  $ 4,606 
Revenues and Expenses
Total revenues $ 16,057  $ 15,388 
Less: Adjustments to total revenues:
Net investment gains (losses) (375) (684)
Net derivative gains (losses) (979) (90)
Investment hedge adjustments (176) (264)
Asymmetrical and non-economic accounting 39  — 
Unit-linked contract income 542  303 
Other adjustments (10) (3)
Divested businesses —  — 
Total adjusted revenues $ 17,016  $ 16,126 
Total expenses $ 15,012  $ 15,131 
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains) losses (694) 188 
Goodwill impairment —  — 
Asymmetrical and non-economic accounting 38  103 
Market volatility (67) (14)
Unit-linked contract costs 539  303 
Other adjustments 16 
Divested businesses 11 
Total adjusted expenses $ 15,185  $ 14,524 
See footnotes on last page.
Page 18 of 24



MetLife, Inc.
(In millions, except per share and ratio data)
For the Three Months Ended
March 31,
2024 2023
Expense Detail and Ratios
Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC
Capitalization of DAC $ (740) $ (718)
Less: Divested businesses —  — 
Adjusted capitalization of DAC $ (740) $ (718)
Reconciliation of Other Expenses to Adjusted Other Expenses
Other expenses $ 3,191  $ 3,057 
Less: Other adjustments 16 
Less: Divested businesses 11 
Adjusted other expenses $ 3,180  $ 3,030 
Other Detail and Ratios
Other expenses, net of capitalization of DAC $ 2,451  $ 2,339 
Premiums, fees and other revenues $ 11,975  $ 11,517 
Expense ratio 20.5  % 20.3  %
Direct expenses $ 1,426  $ 1,387 
Less: Total notable items related to direct expenses (2) —  — 
Direct expenses, excluding total notable items related to direct expenses (2) $ 1,426  $ 1,387 
Adjusted other expenses $ 3,180  $ 3,030 
Adjusted capitalization of DAC (740) (718)
Adjusted other expenses, net of adjusted capitalization of DAC 2,440  2,312 
Less: Total notable items related to adjusted other expenses (2) —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (2) $ 2,440  $ 2,312 
Adjusted premiums, fees and other revenues $ 11,948  $ 11,520 
Less: PRT (25) (21)
Adjusted premiums, fees and other revenues, excluding PRT $ 11,973  $ 11,541 
Direct expense ratio 11.9  % 12.0  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT (2) 11.9  % 12.0  %
Adjusted expense ratio 20.4  % 20.1  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (2) 20.4  % 20.0  %
See footnotes on last page.
Page 19 of 24



MetLife, Inc.
(In millions, except per share data)
March 31,
Equity Details 2024 2023
Total MetLife, Inc.'s stockholders' equity $ 28,535  $ 32,194 
Less: Preferred stock 3,818  3,818 
MetLife, Inc.'s common stockholders' equity 24,717  28,376 
Less: Net unrealized investment gains (losses), net of income tax (16,611) (14,606)
Future policy benefits discount rate remeasurement gain (losses), net of income tax 4,773  2,748 
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax (47) 186 
  Defined benefit plans adjustment, net of income tax (1,421) (1,356)
Total MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA 38,023  41,404 
Less: Accumulated year-to-date total notable items (2) —  — 
Total MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 38,023  $ 41,404 
March 31,
Book Value (3) 2024 2023
Book value per common share $ 34.54  $ 36.89 
Less: Net unrealized investment gains (losses), net of income tax (23.21) (18.99)
Future policy benefits discount rate remeasurement gain (losses), net of income tax 6.68  3.57 
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax (0.07) 0.24 
   Defined benefit plans adjustment, net of income tax (1.99) (1.76)
Book value per common share, excluding AOCI other than FCTA $ 53.13  $ 53.83 
Common shares outstanding, end of period (4) 715.7  769.2 

For the Three Months Ended
March 31, (5)
Return on Equity 2024 2023
Return on MetLife, Inc.'s:
Common stockholders' equity 12.6  % 0.2  %
Adjusted return on MetLife, Inc.'s:
Common stockholders' equity 21.0  % 17.4  %
Common stockholders' equity, excluding AOCI other than FCTA 13.8  % 11.3  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) 13.8  % 11.3  %
For the Three Months Ended
March 31,
Average Common Stockholders' Equity 2024 2023
Average common stockholders' equity $ 25,457  $ 27,220 
Average common stockholders' equity, excluding AOCI other than FCTA $ 38,652  $ 41,856 
Average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 38,652  $ 41,856 
See footnotes on last page.
Page 20 of 24



MetLife, Inc.
Adjusted Earnings Available to Common Shareholders
(In millions)
For the Three Months Ended
March 31,
2024 2023
Group Benefits (6):
Adjusted earnings available to common shareholders $ 284  $ 307 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 284  $ 307 
Adjusted premiums, fees and other revenues $ 6,330  $ 6,049 
Retirement & Income Solutions (6):
Adjusted earnings available to common shareholders $ 399  $ 400 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 399  $ 400 
Adjusted premiums, fees and other revenues $ 813  $ 648 
Less: PRT (25) (21)
Adjusted premiums, fees and other revenues, excluding PRT $ 838  $ 669 
Asia:
Adjusted earnings available to common shareholders $ 423  $ 280 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 423  $ 280 
Adjusted earnings available to common shareholders on a constant currency basis $ 423  $ 269 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 423  $ 269 
Adjusted premiums, fees and other revenues $ 1,744  $ 1,794 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,744  $ 1,659 
Latin America:
Adjusted earnings available to common shareholders $ 233  $ 215 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 233  $ 215 
Adjusted earnings available to common shareholders on a constant currency basis $ 233  $ 221 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 233  $ 221 
Adjusted premiums, fees and other revenues $ 1,496  $ 1,372 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,496  $ 1,380 
See footnotes on last page.
Page 21 of 24



MetLife, Inc.
Adjusted Earnings Available to Common Shareholders (Continued)
(In millions)
For the Three Months Ended
March 31,
2024 2023
EMEA:
Adjusted earnings available to common shareholders $ 77  $ 60 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 77  $ 60 
Adjusted earnings available to common shareholders on a constant currency basis $ 77  $ 57 
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis (2) $ 77  $ 57 
Adjusted premiums, fees and other revenues $ 620  $ 581 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 620  $ 568 
MetLife Holdings (6):
Adjusted earnings available to common shareholders $ 159  $ 158 
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 159  $ 158 
Adjusted premiums, fees and other revenues $ 841  $ 959 
Corporate & Other (6):
Adjusted earnings available to common shareholders $ (241) $ (236)
Less: Total notable items (2) —  — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ (241) $ (236)
Adjusted premiums, fees and other revenues $ 104  $ 117 
See footnotes on last page.









Page 22 of 24



MetLife, Inc.
For the Three Months Ended
March 31,
2024 2023
Variable investment income (post-tax, in millions) (7)
Group Benefits $ $ — 
RIS 73  (3)
Asia 56  (25)
Latin America (2)
EMEA —  — 
MetLife Holdings 55 
Corporate & Other 16  (7)
Total variable investment income $ 205  $ (35)
See footnotes on last page.

Page 23 of 24



MetLife, Inc.
March 31, 2024
Cash & Capital (8), (9), (10) (in billions)
Holding Companies Cash & Liquid Assets
$ 5.2 
Footnotes
(1)
Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.
(2)
Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively.
(3) Book values exclude $3,818 million of equity related to preferred stock at both March 31, 2024 and 2023.
(4) There were share repurchases of approximately $1.2 billion for the three months March 31, 2024. There were share repurchases of approximately $330 million in April 2024.
(5) Annualized using quarter-to-date results.
(6) Results on a constant currency basis are not included as constant currency impact is not significant.
(7)
Assumes a 21% tax rate.
(8) The 2023 combined U.S. risk based capital (RBC) ratio was 407%, which is above MetLife's 360% target on an NAIC basis. This ratio includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company. MetLife calculates RBC annually as of December 31 and, accordingly, the calculation does not reflect conditions and factors occurring after the year end.
(9)
The total U.S. statutory adjusted capital is expected to be approximately $18.3 billion at March 31, 2024, down 6% from December 31, 2023. This balance includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company.
(10)
The expected Japan solvency margin ratio as of March 31, 2024 is approximately 725%.
Page 24 of 24

EX-99.2 3 ex992qfsq124.htm EX-99.2 Document
Exhibit 99.2




 imagk05a.jpg
First Quarter
Financial Supplement
March 31, 2024
1


METLIFE
TABLE OF CONTENTS
 
 
 
 
 
1

METLIFE
As used in this QFS, “MetLife," “we” and “our” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. In this QFS, MetLife presents certain measures of its performance that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of its business. See Appendix for definitions of non-GAAP financial measures and other financial disclosures.
GAAP CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Revenues
Premiums $ 9,589  $ 11,678  $ 11,230  $ 11,786  $ 10,053  $ 9,589  $ 10,053 
Universal life and investment-type product policy fees 1,289  1,288  1,334  1,241  1,248  1,289  1,248 
Net investment income 4,645  5,072  4,825  5,366  5,436  4,645  5,436 
Other revenues 639  621  606  660  674  639  674 
Net investment gains (losses) (684) (1,039) (927) (174) (375) (684) (375)
Net derivative gains (losses) (90) (997) (1,202) 149  (979) (90) (979)
Total revenues 15,388  16,623  15,866  19,028  16,057  15,388  16,057 
Expenses
Policyholder benefits and claims 9,872  11,809  11,130  11,779  10,074  9,872  10,074 
Policyholder liability remeasurement (gains) losses (9) (16) (17) (3) (22) (9) (22)
Market risk benefit remeasurement (gains) losses 188  (817) (796) 431  (694) 188  (694)
Interest credited to policyholder account balances 1,864  1,933  1,658  2,405  2,290  1,864  2,290 
Policyholder dividends 159  151  153  159  147  159  147 
Amortization of DAC and VOBA 470  479  499  504  508  470  508 
Amortization of negative VOBA (7) (6) (7) (6) (6) (7) (6)
Interest expense on debt 255  256  265  269  264  255  264 
Other expenses, net of capitalization of DAC 2,339  2,404  2,447  2,549  2,451  2,339  2,451 
Total expenses 15,131  16,193  15,332  18,087  15,012  15,131  15,012 
Income (loss) before provision for income tax 257  430  534  941  1,045  257  1,045 
Provision for income tax expense (benefit) 172  22  39  327  170  172  170 
Net income (loss) 85  408  495  614  875  85  875 
Less: Net income (loss) attributable to noncontrolling interests
Net income (loss) attributable to MetLife, Inc. 80  402  489  607  867  80  867 
Less: Preferred stock dividends 66  32  67  33  67  66  67 
Net income (loss) available to MetLife, Inc.'s common shareholders $ 14  $ 370  $ 422  $ 574  $ 800  $ 14  $ 800 
Premiums, fees and other revenues $ 11,517  $ 13,587  $ 13,170  $ 13,687  $ 11,975  $ 11,517  $ 11,975 
2

METLIFE
CORPORATE OVERVIEW
For the Three Months Ended
Unaudited (In millions, except per share data) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Net income (loss) available to MetLife, Inc.'s common shareholders $ 14  $ 370  $ 422  $ 574  $ 800 
Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders:
Less: Net investment gains (losses) (684) (1,039) (927) (174) (375)
Less: Net derivative gains (losses) (90) (997) (1,202) 149  (979)
Less: Market risk benefit remeasurement gains (losses) (188) 817  796  (431) 694 
Less: Goodwill impairment —  —  —  —  — 
Less: Other adjustments to net income (loss) (1) (383) (316) (156) (330) (126)
Less: Provision for income tax (expense) benefit 180  419  429  260 
Add: Net income (loss) attributable to noncontrolling interests
Add: Preferred stock redemption premium —  —  —  —  — 
Adjusted earnings available to common shareholders 1,184  1,492  1,488  1,361  1,334 
Less: Total notable items (2) —  —  14  (76) — 
Adjusted earnings available to common shareholders, excluding total notable items (2) $ 1,184  $ 1,492  $ 1,474  $ 1,437  $ 1,334 
Net income (loss) available to MetLife, Inc.'s common shareholders per diluted common share $ 0.02  $ 0.48  $ 0.56  $ 0.77  $ 1.10 
Less: Net investment gains (losses) (0.88) (1.35) (1.23) (0.23) (0.51)
Less: Net derivative gains (losses) (0.12) (1.30) (1.59) 0.20  (1.34)
Less: Market risk benefit remeasurement gains (losses) (0.24) 1.06  1.05  (0.58) 0.95 
Less: Goodwill impairment —  —  —  —  — 
Less: Other adjustments to net income (loss) (0.48) (0.40) (0.20) (0.45) (0.18)
Less: Provision for income tax (expense) benefit 0.23  0.54  0.57  0.01  0.36 
Add: Net income (loss) attributable to noncontrolling interests 0.01  0.01  0.01  0.01  0.01 
Add: Preferred stock redemption premium —  —  —  —  — 
Adjusted earnings available to common shareholders per diluted common share 1.52  1.94  1.97  1.83  1.83 
Less: Total notable items per diluted common share (2) —  —  0.02  (0.10) — 
Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share (2), (3) $ 1.52  $ 1.94  $ 1.95  $ 1.93  $ 1.83 
For the Three Months Ended
Unaudited (In millions, except per share data) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Notable items impacting adjusted earnings available to common shareholders (2):
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 14  $ —  $ — 
Litigation reserves and settlement costs —  —  —  (76) — 
Total notable items  $ —  $ —  $ 14  $ (76) $ — 
Notable items impacting adjusted earnings available to common shareholders per diluted common share (2):
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 0.02  $ —  $ — 
Litigation reserves and settlement costs —  —  —  (0.10) — 
Total notable items  $ —  $ —  $ 0.02  $ (0.10) $ — 
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Weighted average common shares outstanding - diluted 781.2  769.6  755.5  743.4  728.4 
(1)See Appendix for further detail.
(2)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders and adjusted earnings available to common shareholders per diluted common share. The per share data for each notable item is calculated on a standalone basis and may not sum to total notable items. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. See Page A-2 for further detail.
(3)Calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.

3

METLIFE
CORPORATE OVERVIEW (CONTINUED)
Unaudited March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Book value per common share (1) $ 36.89  $ 34.92  $ 29.34  $ 35.85  $ 34.54 
Book value per common share, excluding AOCI other than FCTA (1) $ 53.83  $ 53.55  $ 53.00  $ 53.75  $ 53.13 
For the Three Months Ended
Unaudited March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Return on MetLife, Inc.'s (2):
Common stockholders' equity 0.2  % 5.4  % 7.0  % 9.6  % 12.6  %
Adjusted return on MetLife, Inc.'s (2):
Common stockholders' equity 17.4  % 21.8  % 24.7  % 22.7  % 21.0  %
Common stockholders' equity, excluding AOCI other than FCTA 11.3  % 14.6  % 14.9  % 13.8  % 13.8  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (3) 11.3  % 14.6  % 14.7  % 14.6  % 13.8  %
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Common shares outstanding, beginning of period 779.1  769.2  757.2  744.4  730.8 
Share repurchases (11.6) (12.1) (12.9) (13.7) (16.9)
Newly issued shares 1.7  0.1  0.1  0.1  1.8 
Common shares outstanding, end of period 769.2  757.2  744.4  730.8  715.7 
Weighted average common shares outstanding - basic 775.4  765.9  751.4  738.6  723.2 
Dilutive effect of the exercise or issuance of stock-based awards 5.8  3.7  4.1  4.8  5.2 
Weighted average common shares outstanding - diluted 781.2  769.6  755.5  743.4  728.4 
MetLife Policyholder Trust Shares 122.1  120.5  119.1  117.6  116.0 
(1) Calculated using common shares outstanding, end of period.
(2) Annualized using quarter-to-date results. See Page A-4 for further detail.
(3)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.

4

METLIFE
KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Total revenues $ 15,388  $ 16,623  $ 15,866  $ 19,028  $ 16,057  $ 15,388  $ 16,057 
Less: Adjustments to total revenues:
Net investment gains (losses) (684) (1,039) (927) (174) (375) (684) (375)
Net derivative gains (losses) (90) (997) (1,202) 149  (979) (90) (979)
Investment hedge adjustments (264) (263) (232) (253) (176) (264) (176)
Asymmetrical and non-economic accounting —  —  —  29  39  —  39 
Unit-linked contract income 303  296  580  542  303  542 
Other adjustments (3) (8) (14) (21) (10) (3) (10)
Divested businesses
—  —  —  —  —  —  — 
Total adjusted revenues $ 16,126  $ 18,634  $ 18,237  $ 18,718  $ 17,016  $ 16,126  $ 17,016 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Net investment income $ 4,645  $ 5,072  $ 4,825  $ 5,366  $ 5,436  $ 4,645  $ 5,436 
Less: Adjustments to net investment income:
Investment hedge adjustments (264) (263) (232) (253) (176) (264) (176)
Unit-linked contract income 303  296  580  542  303  542 
Other adjustments —  (1) (3) (8) — 
Divested businesses —  —  —  —  —  —  — 
Adjusted net investment income $ 4,606  $ 5,040  $ 5,056  $ 5,047  $ 5,068  $ 4,606  $ 5,068 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Variable investment income (Included in net investment income above) $ (44) $ 221  $ 179  $ 63  $ 260  $ (44) $ 260 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Premiums, fees and other revenues $ 11,517  $ 13,587  $ 13,170  $ 13,687  $ 11,975  $ 11,517  $ 11,975 
Less: Adjustments to premiums, fees and other revenues:
Asymmetrical and non-economic accounting —  —  —  29  39  —  39 
Other adjustments (3) (7) (11) (13) (12) (3) (12)
Divested businesses
—  —  —  —  —  —  — 
Adjusted premiums, fees and other revenues $ 11,520  $ 13,594  $ 13,181  $ 13,671  $ 11,948  $ 11,520  $ 11,948 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 11,380  $ 13,463  $ 13,097  $ 13,664  $ 11,948 
5

METLIFE
KEY ADJUSTED EARNINGS STATEMENT LINE ITEMS (CONTINUED)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Total expenses $ 15,131  $ 16,193  $ 15,332  $ 18,087  $ 15,012  $ 15,131  $ 15,012 
Less: Adjustments to total expenses:
Market risk benefit remeasurement (gains) losses 188  (817) (796) 431  (694) 188  (694)
Goodwill impairment —  —  —  —  —  —  — 
Asymmetrical and non-economic accounting 103  64  (49) 129  38  103  38 
Market volatility (14) (44) (64) (62) (67) (14) (67)
Unit-linked contract costs 303  301  (3) 582  539  303  539 
Other adjustments 16  11  21  16 
Divested businesses
11  11 
Total adjusted expenses $ 14,524  $ 16,669  $ 16,214  $ 16,991  $ 15,185  $ 14,524  $ 15,185 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Capitalization of DAC $ (718) $ (729) $ (742) $ (728) $ (740) $ (718) $ (740)
Less: Divested businesses —  —  —  —  —  —  — 
Adjusted capitalization of DAC $ (718) $ (729) $ (742) $ (728) $ (740) $ (718) $ (740)
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Other expenses $ 3,057  $ 3,133  $ 3,189  $ 3,277  $ 3,191  $ 3,057  $ 3,191 
Less: Adjustments to other expenses:
Other adjustments 16  11  21  16 
Divested businesses 11  11 
Adjusted other expenses $ 3,030  $ 3,113  $ 3,159  $ 3,261  $ 3,180  $ 3,030  $ 3,180 
Adjusted other expenses on a constant currency basis $ 2,967  $ 3,052  $ 3,128  $ 3,256  $ 3,180 
6

METLIFE
EXPENSE DETAIL AND RATIOS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions, except ratio data) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Other expenses, net of capitalization of DAC $ 2,339  $ 2,404  $ 2,447  $ 2,549  $ 2,451  $ 2,339  $ 2,451 
Premiums, fees and other revenues $ 11,517  $ 13,587  $ 13,170  $ 13,687  $ 11,975  $ 11,517  $ 11,975 
Expense ratio 20.3  % 17.7  % 18.6  % 18.6  % 20.5  % 20.3  % 20.5  %
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted other expenses by major category
Direct expenses $ 1,387  $ 1,415  $ 1,447  $ 1,559  $ 1,426  $ 1,387  $ 1,426 
Pension, postretirement and postemployment benefit costs 59  59  59  69  65  59  65 
Premium taxes, other taxes, and licenses & fees 161  184  162  153  176  161  176 
Commissions and other variable expenses 1,423  1,455  1,491  1,480  1,513  1,423  1,513 
Adjusted other expenses
3,030  3,113  3,159  3,261  3,180  3,030  3,180 
Adjusted capitalization of DAC (718) (729) (742) (728) (740) (718) (740)
Adjusted other expenses, net of adjusted capitalization of DAC
$ 2,312  $ 2,384  $ 2,417  $ 2,533  $ 2,440  $ 2,312  $ 2,440 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions, except ratio data) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Employee-related costs $ 929  $ 895  $ 913  $ 882  $ 950  $ 929  $ 950 
Third-party staffing costs 331  346  350  399  342  331  342 
General and administrative expenses 127  174  184  278  134  127  134 
Direct expenses 1,387  1,415  1,447  1,559  1,426  1,387  1,426 
Less: Total notable items related to direct expenses (1) —  —  —  96  —  —  — 
Direct expenses, excluding total notable items related to direct expenses (1) $ 1,387  $ 1,415  $ 1,447  $ 1,463  $ 1,426  $ 1,387  $ 1,426 
Adjusted other expenses, net of adjusted capitalization of DAC
$ 2,312  $ 2,384  $ 2,417  $ 2,533  $ 2,440  $ 2,312  $ 2,440 
Less: Total notable items related to adjusted other expenses (1) —  —  —  96  —  —  — 
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (1)
$ 2,312  $ 2,384  $ 2,417  $ 2,437  $ 2,440  $ 2,312  $ 2,440 
Adjusted premiums, fees and other revenues $ 11,520  $ 13,594  $ 13,181  $ 13,671  $ 11,948  $ 11,520  $ 11,948 
Less: PRT (21) 2,024  1,461  1,860  (25) (21) (25)
Adjusted premiums, fees and other revenues, excluding PRT $ 11,541  $ 11,570  $ 11,720  $ 11,811  $ 11,973  $ 11,541  $ 11,973 
Direct expense ratio 12.0  % 10.4  % 11.0  % 11.4  % 11.9  % 12.0  % 11.9  %
Direct expense ratio, excluding total notable items related to direct expenses and PRT (1) 12.0  % 12.2  % 12.3  % 12.4  % 11.9  % 12.0  % 11.9  %
Adjusted expense ratio 20.1  % 17.5  % 18.3  % 18.5  % 20.4  % 20.1  % 20.4  %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (1) 20.0  % 20.6  % 20.6  % 20.6  % 20.4  % 20.0  % 20.4  %
(1)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.

7

METLIFE
GAAP CONSOLIDATED BALANCE SHEETS
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
ASSETS
Investments:
Fixed maturity securities available-for-sale, at estimated fair value $ 283,854  $ 283,857  $ 270,982  $ 281,412  $ 278,409 
Equity securities, at estimated fair value 1,695  769  742  757  750 
Contractholder-directed equity securities and fair value option securities, at estimated fair value 10,063  10,204  9,680  10,331  10,313 
Mortgage loans 85,572  92,986  92,230  92,506  91,458 
Policy loans 8,863  8,788  8,725  8,788  8,800 
Real estate and real estate joint ventures 13,155  13,045  13,133  13,332  12,992 
Other limited partnership interests 14,437  14,722  14,918  14,764  14,301 
Short-term investments, principally at estimated fair value 4,184  6,921  6,497  6,045  4,884 
Other invested assets 19,479  19,656  18,755  18,202  18,097 
Total investments 441,302  450,948  435,662  446,137  440,004 
Cash and cash equivalents, principally at estimated fair value 18,456  15,417  14,912  20,639  19,840 
Accrued investment income 3,554  3,505  3,704  3,589  3,636 
Premiums, reinsurance and other receivables 18,692  18,530  19,002  28,971  29,986 
Market risk benefits, at estimated fair value 227  279  334  286  351 
Deferred policy acquisition costs and value of business acquired 19,976  19,850  19,737  20,151  19,842 
Current income tax recoverable —  189  —  190  — 
Deferred income tax assets 2,257  2,377  3,174  2,612  2,751 
Goodwill 9,379  9,261  9,109  9,236  9,037 
Other assets 12,006  10,977  10,862  11,139  11,126 
Separate account assets 148,417  145,946  135,624  144,634  141,003 
Total assets $ 674,266  $ 677,279  $ 652,120  $ 687,584  $ 677,576 
LIABILITIES AND EQUITY
Liabilities
Future policy benefits $ 191,741  $ 190,474  $ 181,755  $ 196,406  $ 191,013 
Policyholder account balances 212,569  214,413  213,933  219,269  219,168 
Market risk benefits, at estimated fair value 3,869  3,259  2,738  3,179  2,696 
Other policy-related balances 19,598  19,642  19,665  19,736  20,219 
Policyholder dividends payable 356  366  381  386  357 
Payables for collateral under securities loaned and other transactions 19,863  18,806  17,797  17,524  17,470 
Short-term debt 168  200  161  119  127 
Long-term debt 14,622  14,539  15,475  15,548  15,972 
Collateral financing arrangement 704  675  651  637  590 
Junior subordinated debt securities 3,159  3,160  3,160  3,161  3,162 
Current income tax payable 554  —  59  —  10 
Deferred income tax liability 1,111  752  128  927  835 
Other liabilities 25,112  34,555  34,698  35,805  36,158 
Separate account liabilities 148,417  145,946  135,624  144,634  141,003 
Total liabilities 641,843  646,787  626,225  657,331  648,780 
Equity
Preferred stock, at par value —  —  —  —  — 
Common stock, at par value 12  12  12  12  12 
Additional paid-in capital 33,617  33,630  33,666  33,690  33,718 
Retained earnings 39,957  39,928  39,958  40,146  40,350 
Treasury stock, at cost (22,245) (22,923) (23,724) (24,591) (25,774)
Accumulated other comprehensive income (loss) (19,147) (20,386) (24,254) (19,242) (19,771)
Total MetLife, Inc.'s stockholders' equity 32,194  30,261  25,658  30,015  28,535 
Noncontrolling interests 229  231  237  238  261 
Total equity 32,423  30,492  25,895  30,253  28,796 
Total liabilities and equity $ 674,266  $ 677,279  $ 652,120  $ 687,584  $ 677,576 
8

METLIFE
SUMMARY OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS (1)
   For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Adjusted earnings before provision for income tax
GROUP BENEFITS $ 391  $ 471  $ 645  $ 590  $ 359 
RIS 505  527  594  532  504 
ASIA 405  611  405  419  582 
LATIN AMERICA 303  281  282  271  331 
EMEA 76  92  112  63  103 
METLIFE HOLDINGS 195  262  259  193  196 
CORPORATE & OTHER (273) (279) (274) (341) (244)
Total adjusted earnings before provision for income tax
$ 1,602  $ 1,965  $ 2,023  $ 1,727  $ 1,831 
Provision for income tax expense (benefit)
GROUP BENEFITS $ 84  $ 99  $ 135  $ 124  $ 75 
RIS 105  110  124  111  105 
ASIA 125  180  130  123  159 
LATIN AMERICA 88  62  83  64  98 
EMEA 16  22  24  16  26 
METLIFE HOLDINGS 37  51  51  37  37 
CORPORATE & OTHER (103) (83) (79) (142) (70)
Total provision for income tax expense (benefit)
$ 352  $ 441  $ 468  $ 333  $ 430 
Adjusted earnings available to common shareholders
GROUP BENEFITS $ 307  $ 372  $ 510  $ 466  $ 284 
RIS 400  417  470  421  399 
ASIA 280  431  275  296  423 
LATIN AMERICA 215  219  199  207  233 
EMEA 60  70  88  47  77 
METLIFE HOLDINGS 158  211  208  156  159 
CORPORATE & OTHER (2) (236) (228) (262) (232) (241)
Total adjusted earnings available to common shareholders (2) $ 1,184  $ 1,492  $ 1,488  $ 1,361  $ 1,334 
(1)Includes impact of preferred stock dividends of $66 million, $32 million, $67 million, $33 million and $67 million for the three months ended March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and March 31, 2024, respectively.
9

GROUP BENEFITS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 5,451  $ 5,427  $ 5,276  $ 5,404  $ 5,711  $ 5,451  $ 5,711 
Universal life and investment-type product policy fees 218  223  219  218  222  218  222 
Net investment income 310  327  330  334  315  310  315 
Other revenues 380  363  371  379  397  380  397 
Total adjusted revenues 6,359  6,340  6,196  6,335  6,645  6,359  6,645 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 4,994  4,866  4,592  4,712  5,236  4,994  5,236 
Policyholder liability remeasurement (gains) losses (4) (29) (3) (4) (3)
Interest credited to policyholder account balances 46  48  50  49  48  46  48 
Capitalization of DAC (6) (5) (5) (4) (4) (6) (4)
Amortization of DAC and VOBA
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt —  —  —  —  — 
Other expenses 932  950  937  977  1,003  932  1,003 
Total adjusted expenses 5,968  5,869  5,551  5,745  6,286  5,968  6,286 
Adjusted earnings before provision for income tax 391  471  645  590  359  391  359 
Provision for income tax expense (benefit) 84  99  135  124  75  84  75 
Adjusted earnings 307  372  510  466  284  307  284 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 307  $ 372  $ 510  $ 466  $ 284  $ 307  $ 284 
Adjusted premiums, fees and other revenues $ 6,049  $ 6,013  $ 5,866  $ 6,001  $ 6,330  $ 6,049  $ 6,330 
10

GROUP BENEFITS
OTHER EXPENSES BY MAJOR CATEGORY
   For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Direct and allocated expenses $ 474  $ 468  $ 464  $ 490  $ 505 
Pension, postretirement and postemployment benefit costs 13  13  12  12  14 
Premium taxes, other taxes, and licenses & fees 80  101  83  79  89 
Commissions and other variable expenses 365  368  378  396  395 
Adjusted other expenses $ 932  $ 950  $ 937  $ 977  $ 1,003 
OTHER STATISTICAL INFORMATION (1)
   For the Three Months Ended
Unaudited (In millions, except ratios) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Group Life (2)
Adjusted premiums, fees and other revenues $ 2,232  $ 2,254  $ 2,215  $ 2,199  $ 2,340 
Mortality ratio 90.5  % 85.3  % 83.6  % 83.5  % 90.2  %
Group Non-Medical Health (3)
Adjusted premiums, fees and other revenues $ 2,601  $ 2,617  $ 2,620  $ 2,689  $ 2,773 
Interest adjusted benefit ratio (4) 72.9  % 73.7  % 69.0  % 70.7  % 73.9  %
(1) Results are derived from insurance and non-administrative services-only contracts.
(2) Excludes certain experience-rated contracts and includes accidental death and dismemberment.
(3) Primarily includes dental, group and individual disability, accident & health, critical illness and vision.
(4) Reflects actual claims experience and excludes the impact of interest credited on future policyholder benefits. The product within Group Non-Medical Health with interest credited on future policyholder benefits is disability.
11

RIS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 501  $ 2,681  $ 2,330  $ 2,736  $ 675  $ 501  $ 675 
Universal life and investment-type product policy fees 79  71  82  81  75  79  75 
Net investment income 1,814  1,948  2,009  2,032  2,089  1,814  2,089 
Other revenues 68  71  66  66  63  68  63 
Total adjusted revenues 2,462  4,771  4,487  4,915  2,902  2,462  2,902 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,225  3,441  3,100  3,503  1,471  1,225  1,471 
Policyholder liability remeasurement (gains) losses (29) (11) (76) (15) (29)
Interest credited to policyholder account balances 646  702  756  783  796  646  796 
Capitalization of DAC (45) (50) (41) (40) (61) (45) (61)
Amortization of DAC and VOBA 11  12  13  13  15  11  15 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 146  146  138  135  172  146  172 
Total adjusted expenses 1,957  4,244  3,893  4,383  2,398  1,957  2,398 
Adjusted earnings before provision for income tax 505  527  594  532  504  505  504 
Provision for income tax expense (benefit) 105  110  124  111  105  105  105 
Adjusted earnings 400  417  470  421  399  400  399 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 400  $ 417  $ 470  $ 421  $ 399  $ 400  $ 399 
Adjusted premiums, fees and other revenues $ 648  $ 2,823  $ 2,478  $ 2,883  $ 813  $ 648  $ 813 
Less: PRT
(21) 2,024  1,461  1,860  (25) (21) (25)
Adjusted premiums, fees and other revenues, excluding PRT $ 669  $ 799  $ 1,017  $ 1,023  $ 838  $ 669  $ 838 
12

RIS
FUTURE POLICY BENEFITS (1)
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Balance, end of period (at balance sheet discount rate) (2) $ 63,671  $ 64,446  $ 61,947  $ 69,407  $ 67,402 
Less: Accumulated other comprehensive (income) loss (1,302) (2,135) (5,598) (278) (1,735)
Balance, end of period (at original discount rate) $ 64,973  $ 66,581  $ 67,545  $ 69,685  $ 69,137 
POLICYHOLDER ACCOUNT BALANCES
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Balance, end of period $ 79,973  $ 81,249  $ 80,929  $ 82,405  $ 83,049 
SEPARATE ACCOUNT LIABILITIES
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Balance, end of period $ 57,990  $ 54,501  $ 51,740  $ 53,093  $ 51,012 
SYNTHETIC GICS (3), (4)
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Balance, end of period $ 47,850  $ 50,453  $ 49,003  $ 49,066  $ 48,100 
LONGEVITY REINSURANCE (5)
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Balance, end of period $ 17,085  $ 19,401  $ 19,175  $ 21,945  $ 21,333 
(1)Includes $3,449 million, $3,481 million, $3,731 million, $3,782 and $3,791 million of DPL at March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, respectively.
(2)Represents the current discount rate at the respective balance sheet date.
(3)A synthetic GIC is a contract that simulates the performance of a traditional GIC through the use of financial instruments and is reported as a derivative. A key difference between a synthetic GIC and a traditional GIC is that the contractholder owns the assets underlying the synthetic GIC. The assets and corresponding contractholder account balance are not on MetLife, Inc.'s consolidated balance sheet, as they are for a traditional GIC. The contractholder account balance is reported at contract value in the table above.
(4)Includes $2,262 million, $3,112 million, $0, $1,282 million and $0 of transfers from separate account GICs to synthetic GICs at March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, respectively. These transfers are reported as surrenders and withdrawals on the separate account liabilities table and premiums and deposits on the synthetic GICs table.
(5)The contract value presented represents notional amounts based on the present value of fixed annuity premiums related to longevity reinsurance contracts associated with the United Kingdom pension risk transfer market.
13

RIS
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Direct and allocated expenses $ 71  $ 67  $ 66  $ 71  $ 80 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 12  17 
Commissions and other variable expenses 63  64  59  60  71 
Adjusted other expenses $ 146  $ 146  $ 138  $ 135  $ 172 
SPREAD
For the Three Months Ended
Unaudited March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Investment income yield excluding variable investment income yield 4.98  % 5.18  % 5.28  % 5.32  % 5.24  %
Variable investment income yield (0.27) % 2.57  % 3.08  % 1.96  % 6.30  %
Total investment income yield 4.78  % 5.08  % 5.20  % 5.19  % 5.28  %
Average crediting rate 3.82  % 3.97  % 4.12  % 4.20  % 4.23  %
Amortization of DPL and losses at inception (1) (0.21) % (0.21) % (0.22) % (0.22) % (0.22) %
Total average crediting rate 3.61  % 3.76  % 3.90  % 3.98  % 4.01  %
Annualized general account spread 1.17  % 1.32  % 1.30  % 1.21  % 1.27  %
Annualized general account spread excluding variable investment income yield 1.37  % 1.42  % 1.38  % 1.34  % 1.23  %
(1)Includes the amortization of DPL of (0.22)%, (0.21)%, (0.23)%, (0.23)% and (0.23)% for the three months ended March 31, 2023, June 30, 2023. September 30, 2023, December 31, 2023 and March 31, 2024, respectively.
14

ASIA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 1,377  $ 1,310  $ 1,312  $ 1,252  $ 1,297  $ 1,377  $ 1,297 
Universal life and investment-type product policy fees 397  396  411  428  426  397  426 
Net investment income 881  1,050  1,023  1,003  1,108  881  1,108 
Other revenues 20  21  20  25  21  20  21 
Total adjusted revenues 2,675  2,777  2,766  2,708  2,852  2,675  2,852 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,130  1,057  1,095  1,051  1,067  1,130  1,067 
Policyholder liability remeasurement (gains) losses 11  (27) 108  13  (32) 11  (32)
Interest credited to policyholder account balances 536  570  576  619  647  536  647 
Capitalization of DAC (401) (397) (404) (381) (361) (401) (361)
Amortization of DAC and VOBA 193  190  204  207  210  193  210 
Amortization of negative VOBA (6) (5) (6) (5) (5) (6) (5)
Interest expense on debt —  —  —  —  —  —  — 
Other expenses 807  778  788  785  744  807  744 
Total adjusted expenses 2,270  2,166  2,361  2,289  2,270  2,270  2,270 
Adjusted earnings before provision for income tax 405  611  405  419  582  405  582 
Provision for income tax expense (benefit) 125  180  130  123  159  125  159 
Adjusted earnings 280  431  275  296  423  280  423 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 280  $ 431  $ 275  $ 296  $ 423  $ 280  $ 423 
Adjusted premiums, fees and other revenues $ 1,794  $ 1,727  $ 1,743  $ 1,705  $ 1,744  $ 1,794  $ 1,744 
15

ASIA
ADJUSTED PREMIUMS, FEES AND OTHER REVENUES
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Adjusted premiums, fees and other revenues $ 1,794  $ 1,727  $ 1,743  $ 1,705  $ 1,744 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,659  $ 1,645  $ 1,712  $ 1,697  $ 1,744 
Add: Operating joint ventures, on a constant currency basis (1) 481  411  427  367  528 
Adjusted premiums, fees and other revenues, including operating joint ventures, on a constant currency basis $ 2,140  $ 2,056  $ 2,139  $ 2,064  $ 2,272 
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Direct and allocated expenses $ 303  $ 285  $ 284  $ 300  $ 282 
Pension, postretirement and postemployment benefit costs 17  15  16  20  15 
Premium taxes, other taxes, and licenses & fees 33  32  33  34  33 
Commissions and other variable expenses 454  446  455  431  414 
Adjusted other expenses $ 807  $ 778  $ 788  $ 785  $ 744 
Adjusted other expenses, net of adjusted capitalization of DAC $ 406  $ 381  $ 384  $ 404  $ 383 
Adjusted other expenses on a constant currency basis $ 740  $ 735  $ 772  $ 779  $ 744 
Add: Operating joint ventures, on a constant currency basis (2) 124  116  114  98  116 
Adjusted other expenses, including operating joint ventures, on a constant currency basis $ 864  $ 851  $ 886  $ 877  $ 860 
Adjusted other expenses, including operating joint ventures, net of adjusted capitalization of DAC, on a constant currency basis
$ 467  $ 443  $ 465  $ 483  $ 451 
SALES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Japan:
Life $ 82  $ 198  $ 177  $ 194  $ 135 
Accident & Health 61  59  52  59  71 
Annuities 263  173  146  178  148 
Other
Total Japan 408  432  377  432  356 
Other Asia 226  181  222  180  228 
   Total sales $ 634  $ 613  $ 599  $ 612  $ 584 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Adjusted earnings available to common shareholders $ 280  $ 431  $ 275  $ 296  $ 423 
Adjusted earnings available to common shareholders, on a constant currency basis $ 269  $ 422  $ 273  $ 296  $ 423 
(1)Includes MetLife, Inc.'s share of adjusted premiums, fees and other revenues for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
(2)Includes MetLife, Inc.'s share of adjusted other expenses for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.

16

ASIA
ASIA GENERAL ACCOUNT ASSETS UNDER MANAGEMENT AND RELATED MEASURES
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
GA AUM $ 121,072  $ 118,188  $ 113,105  $ 123,434  $ 120,743 
GA AUM (at amortized cost) $ 127,120  $ 125,266  $ 124,684  $ 130,093  $ 128,618 
GA AUM (at amortized cost), on a constant currency basis $ 121,057  $ 123,165  $ 124,216  $ 126,558  $ 128,618 
  Add: Operating joint ventures, on a constant currency basis (1) 7,842  8,139  8,325  7,985  8,265 
GA AUM (at amortized cost), including operating joint ventures, on a constant currency basis $ 128,899  $ 131,304  $ 132,541  $ 134,543  $ 136,883 
(1)Includes MetLife, Inc.'s share of GA AUM for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
17

LATIN AMERICA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 1,025  $ 1,023  $ 1,116  $ 1,123  $ 1,115  $ 1,025  $ 1,115 
Universal life and investment-type product policy fees 335  352  359  352  370  335  370 
Net investment income 379  418  365  482  386  379  386 
Other revenues 12  10  11  11  12  11 
Total adjusted revenues 1,751  1,803  1,849  1,968  1,882  1,751  1,882 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 966  976  1,020  1,132  983  966  983 
Policyholder liability remeasurement (gains) losses (4) (4) (20) (8) (4) (8)
Interest credited to policyholder account balances 99  105  106  116  114  99  114 
Capitalization of DAC (151) (148) (171) (181) (178) (151) (178)
Amortization of DAC and VOBA 106  117  121  124  125  106  125 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 430  465  493  523  512  430  512 
Total adjusted expenses 1,448  1,522  1,567  1,697  1,551  1,448  1,551 
Adjusted earnings before provision for income tax 303  281  282  271  331  303  331 
Provision for income tax expense (benefit) 88  62  83  64  98  88  98 
Adjusted earnings 215  219  199  207  233  215  233 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 215  $ 219  $ 199  $ 207  $ 233  $ 215  $ 233 
Adjusted premiums, fees and other revenues $ 1,372  $ 1,385  $ 1,484  $ 1,486  $ 1,496  $ 1,372  $ 1,496 
18

LATIN AMERICA
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Direct and allocated expenses $ 133  $ 143  $ 148  $ 154  $ 140 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 21  20  19  29  20 
Commissions and other variable expenses 275  301  325  339  350 
Adjusted other expenses $ 430  $ 465  $ 493  $ 523  $ 512 
Adjusted other expenses, net of adjusted capitalization of DAC $ 279  $ 317  $ 322  $ 342  $ 334 
Adjusted other expenses on a constant currency basis $ 443  $ 459  $ 483  $ 526  $ 512 
Adjusted other expenses, net of adjusted capitalization of DAC, on a constant currency basis $ 285  $ 312  $ 315  $ 343  $ 334 
SALES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Mexico $ 224  $ 160  $ 199  $ 167  238 
Chile 87  85  89  93  94 
All other 100  84  80  85  79 
Total sales $ 411  $ 329  $ 368  $ 345  $ 411 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Adjusted premiums, fees and other revenues $ 1,372  $ 1,385  $ 1,484  $ 1,486  $ 1,496 
Adjusted earnings available to common shareholders $ 215  $ 219  $ 199  $ 207  $ 233 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 1,380  $ 1,353  $ 1,440  $ 1,489  $ 1,496 
Adjusted earnings available to common shareholders, on a constant currency basis $ 221  $ 213  $ 194  $ 206  $ 233 

19

EMEA
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
 
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 496  $ 499  $ 502  $ 519  $ 536  $ 496  $ 536 
Universal life and investment-type product policy fees 77  75  79  67  77  77  77 
Net investment income 45  47  51  54  54  45  54 
Other revenues
Total adjusted revenues 626  629  639  649  674  626  674 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 261  237  230  256  258  261  258 
Policyholder liability remeasurement (gains) losses (3) (9) —  (3) — 
Interest credited to policyholder account balances 16  19  19  18  19  16  19 
Capitalization of DAC (108) (119) (114) (116) (128) (108) (128)
Amortization of DAC and VOBA 85  85  87  91  91  85  91 
Amortization of negative VOBA (1) (1) (1) (1) (1) (1) (1)
Interest expense on debt —  —  —  —  —  —  — 
Other expenses 300  314  315  331  332  300  332 
Total adjusted expenses 550  537  527  586  571  550  571 
Adjusted earnings before provision for income tax 76  92  112  63  103  76  103 
Provision for income tax expense (benefit) 16  22  24  16  26  16  26 
Adjusted earnings 60  70  88  47  77  60  77 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 60  $ 70  $ 88  $ 47  $ 77  $ 60  $ 77 
Adjusted premiums, fees and other revenues $ 581  $ 582  $ 588  $ 595  $ 620  $ 581  $ 620 
20

EMEA
OTHER EXPENSES BY MAJOR CATEGORY
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Direct and allocated expenses $ 94  $ 97  $ 104  $ 109  $ 101 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees
Commissions and other variable expenses 200  210  203  210  224 
Adjusted other expenses $ 300  $ 314  $ 315  $ 331  $ 332 
Adjusted other expenses, net of adjusted capitalization of DAC $ 192  $ 195  $ 201  $ 215  $ 204 
Adjusted other expenses on a constant currency basis $ 291  $ 302  $ 310  $ 329  $ 332 
Adjusted other expenses, net of adjusted capitalization of DAC, on a constant currency basis $ 188  $ 190  $ 199  $ 214  $ 204 
OTHER STATISTICAL INFORMATION
   For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Adjusted premiums, fees and other revenues $ 581  $ 582  $ 588  $ 595  $ 620 
Adjusted earnings available to common shareholders $ 60  $ 70  $ 88  $ 47  $ 77 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 568  $ 565  $ 579  $ 593  $ 620 
Adjusted earnings available to common shareholders, on a constant currency basis $ 57  $ 66  $ 87  $ 48  $ 77 
Total sales on a constant currency basis $ 252  $ 219  $ 195  $ 205  $ 292 
21

METLIFE HOLDINGS
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 723  $ 719  $ 685  $ 754  $ 713  $ 723  $ 713 
Universal life and investment-type product policy fees 183  170  184  95  78  183  78 
Net investment income 1,127  1,170  1,153  1,044  1,010  1,127  1,010 
Other revenues 53  49  41  52  50  53  50 
Total adjusted revenues 2,086  2,108  2,063  1,945  1,851  2,086  1,851 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 1,369  1,341  1,311  1,329  1,251  1,369  1,251 
Policyholder liability remeasurement (gains) losses 20  15  (7) 20  20  20 
Interest credited to policyholder account balances 199  198  198  135  103  199  103 
Capitalization of DAC (6) (6) (5) (5) (5) (6) (5)
Amortization of DAC and VOBA 68  64  65  61  59  68  59 
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt
Other expenses 238  231  238  220  223  238  223 
Total adjusted expenses 1,891  1,846  1,804  1,752  1,655  1,891  1,655 
Adjusted earnings before provision for income tax 195  262  259  193  196  195  196 
Provision for income tax expense (benefit) 37  51  51  37  37  37  37 
Adjusted earnings 158  211  208  156  159  158  159 
Preferred stock dividends —  —  —  —  —  —  — 
Adjusted earnings available to common shareholders $ 158  $ 211  $ 208  $ 156  $ 159  $ 158  $ 159 
Adjusted premiums, fees and other revenues $ 959  $ 938  $ 910  $ 901  $ 841  $ 959  $ 841 
22

METLIFE HOLDINGS
FUTURE POLICY BENEFITS (1)
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Annuities $ 1,606  $ 1,581  $ 1,508  $ 1,610  $ 1,577 
Life and Other 54,365  54,187  53,930  53,930  53,604 
Long Term Care 14,617  14,498  13,025  15,240  14,845 
Balance, end of period (at balance sheet discount rate) (2) $ 70,588  $ 70,266  $ 68,463  $ 70,780  $ 70,026 
Less:
Annuities $ (29) $ (50) $ (110) $ (18) $ (46)
Life and Other (16) 18  (120) 27  (2)
Long Term Care 111  (172) (1,754) 313  (215)
Accumulated other comprehensive (income) loss $ 66  $ (204) $ (1,984) $ 322  $ (263)
Annuities $ 1,635  $ 1,631  $ 1,618  $ 1,628  $ 1,623 
Life and Other 54,381  54,169  54,050  53,903  53,606 
Long Term Care 14,506  14,670  14,779  14,927  15,060 
Balance, end of period (at original discount rate) $ 70,522  $ 70,470  $ 70,447  $ 70,458  $ 70,289 
Future policy benefits subject to reinsurance (at balance sheet discount rate) (3)
Annuities $ —  $ —  $ —  $ 1,519  $ 1,526 
Life and Other $ 1,038  $ 1,030  $ 1,044  $ 2,341  $ 2,345 
Long Term Care $ —  $ —  $ —  $ —  $ — 
POLICYHOLDER ACCOUNT BALANCES
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Annuities $ 12,818  $ 12,410  $ 12,006  $ 11,537  $ 11,129 
Life and Other 12,234  12,044  11,844  11,641  11,486 
Balance, end of period $ 25,052  $ 24,454  $ 23,850  $ 23,178  $ 22,615 
Policyholder account balances subject to reinsurance (3)
Annuities $ —  $ —  $ —  $ 3,485  $ 3,345 
Life and Other $ 1,555  $ 1,548  $ 1,542  $ 6,352  $ 6,532 
MARKET RISK BENEFITS (4)
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Annuities $ 3,361  $ 2,793  $ 2,268  $ 2,722  $ 2,231 
Balance, end of period $ 3,361  $ 2,793  $ 2,268  $ 2,722  $ 2,231 
Market risk benefits subject to reinsurance $ —  $ —  $ —  $ —  $ — 
SEPARATE ACCOUNT LIABILITIES
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Annuities $ 29,320  $ 29,616  $ 27,455  $ 29,224  $ 29,866 
Life and Other 5,794  6,071  5,736  6,324  6,757 
Balance, end of period $ 35,114  $ 35,687  $ 33,191  $ 35,548  $ 36,623 
Separate accounts liabilities subject to modified coinsurance (5)
Annuities $ —  $ —  $ —  $ 83  $ 85 
Life and Other $ —  $ —  $ —  $ 5,597  $ 5,980 
(1) Includes participating life contracts, additional liabilities for annuitization, death and other insurance benefits, as well as DPL.
(2) Represents the current discount rate at the respective balance sheet date.
(3) Included in premiums, reinsurance and other receivables on MetLife, Inc.'s consolidated balance sheets.
(4) Market risk benefits include Japan reinsurance.
(5) Separate account assets retained by MetLife; these amounts are not included in premiums, reinsurance and other receivables on MetLife, Inc.'s consolidated balance sheets.
23

METLIFE HOLDINGS
OTHER EXPENSES BY MAJOR CATEGORY
   For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Direct and allocated expenses $ 171  $ 165  $ 166  $ 164  $ 165 
Pension, postretirement and postemployment benefit costs
Premium taxes, other taxes, and licenses & fees 18  17  19  16  16 
Commissions and other variable expenses 43  43  48  34  36 
Adjusted other expenses $ 238  $ 231  $ 238  $ 220  $ 223 
OTHER STATISTICAL INFORMATION
For the Three Months Ended
Unaudited (In millions, except ratios) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Lapse Ratio (1)
Traditional life 4.7  % 4.8  % 5.1  % 5.4  % 5.7  %
Variable annuity 9.5  % 9.9  % 10.5  % 11.1  % 11.6  %
(1) Lapse ratios are calculated based on the average of the most recent 12 months of experience.

24

CORPORATE & OTHER
STATEMENTS OF ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Adjusted revenues
Premiums $ 16  $ 19  $ $ (2) $ $ 16  $
Universal life and investment-type product policy fees —  —  —  —  —  — 
Net investment income 50  80  125  98  106  50  106 
Other revenues 101  106  103  102  98  101  98 
Total adjusted revenues 167  206  237  198  210  167  210 
Adjusted expenses
Policyholder benefits and claims and policyholder dividends 16  12  (9) 16 
Policyholder liability remeasurement (gains) losses —  —  —  —  —  —  — 
Interest credited to policyholder account balances —  —  —  —  —  —  — 
Capitalization of DAC (1) (4) (2) (1) (3) (1) (3)
Amortization of DAC and VOBA
Amortization of negative VOBA —  —  —  —  —  —  — 
Interest expense on debt 247  244  256  258  253  247  253 
Other expenses 177  229  250  290  194  177  194 
Total adjusted expenses 440  485  511  539  454  440  454 
Adjusted earnings before provision for income tax (273) (279) (274) (341) (244) (273) (244)
Provision for income tax expense (benefit) (103) (83) (79) (142) (70) (103) (70)
Adjusted earnings (170) (196) (195) (199) (174) (170) (174)
Preferred stock dividends 66  32  67  33  67  66  67 
Adjusted earnings available to common shareholders $ (236) $ (228) $ (262) $ (232) $ (241) $ (236) $ (241)
Adjusted premiums, fees and other revenues $ 117  $ 126  $ 112  $ 100  $ 104  $ 117  $ 104 
ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS BY SOURCE
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Business activities $ 19  $ 20  $ 13  $ 35  $ $ 19  $
Net investment income 51  81  126  95  102  51  102 
Interest expense on debt (258) (254) (266) (269) (265) (258) (265)
Corporate initiatives and projects (14) (32) (12) (9) (6) (14) (6)
Other (71) (94) (135) (193) (81) (71) (81)
Provision for income tax (expense) benefit and other tax-related items 103  83  79  142  70  103  70 
Preferred stock dividends (66) (32) (67) (33) (67) (66) (67)
Adjusted earnings available to common shareholders $ (236) $ (228) $ (262) $ (232) $ (241) $ (236) $ (241)
25

INVESTMENTS
INVESTMENT PORTFOLIO RESULTS BY ASSET CATEGORY AND ANNUALIZED YIELDS
This yield table presentation is consistent with how we measure our investment performance for management purposes, and we believe it enhances understanding of our investment portfolio results.
At or For the Three Months Ended At or For the Year-to-Date Period Ended
Unaudited (In millions, except yields) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Fixed Maturity Securities
Yield (1) 4.07  % 4.17  % 4.19  % 4.39  % 4.38  % 4.07  % 4.38  %
Investment income (2), (3) $ 3,028  $ 3,107  $ 3,123  $ 3,241  $ 3,200  $ 3,028  $ 3,200 
Investment gains (losses) (580) (996) (699) (197) (85) (580) (85)
Ending carrying value (4) 285,397  285,444  272,456  282,861  279,855  285,397  279,855 
Net Mortgage Loans
Yield (1) 4.92  % 5.12  % 5.18  % 5.36  % 5.25  % 4.92  % 5.25  %
Investment income (3) 1,041  1,091  1,094  1,127  1,100  1,041  1,100 
Investment gains (losses) (164) 32  (69) (82) (164) (82)
Ending carrying value (5) 85,572  84,794  84,058  84,118  83,452  85,572  83,452 
Real Estate and Real Estate Joint Ventures
Yield (1) (2.10) % 0.82  % (0.31) % 2.08  % (2.74) % (2.10) % (2.74) %
Investment income (69) 27  (11) 69  (90) (69) (90)
Investment gains (losses) 18  13  37  35  18  35 
Ending carrying value 13,155  13,045  13,133  13,332  12,992  13,155  12,992 
Policy Loans
Yield (1) 5.35  % 5.39  % 5.52  % 5.36  % 5.56  % 5.35  % 5.56  %
Investment income 119  119  120  113  113  119  113 
Ending carrying value 8,863  8,788  8,725  8,788  8,800  8,863  8,800 
Equity Securities
Yield (1) 3.17  % 4.11  % 4.14  % 3.37  % 5.48  % 3.17  % 5.48  %
Investment income 12  10  12 
Investment gains (losses) 48  32  (14) 15  28  48  28 
Ending carrying value 1,695  769  742  757  750  1,695  750 
Other Limited Partnership Interests
Yield (1), (6) 0.73  % 6.17  % 5.56  % (0.06) % 8.27  % 0.73  % 8.27  %
Investment income (6) 26  225  206  (2) 301  26  301 
Investment gains (losses) —  —  (50) (50)
Ending carrying value (7) 14,437  14,722  14,918  14,764  14,301  14,437  14,301 
Cash and Short-term Investments
Yield (1) 5.01  % 5.94  % 6.38  % 5.61  % 5.32  % 5.01  % 5.32  %
Investment income 167  195  220  229  246  167  246 
Investment gains (losses) (11) 29  (33) 25  (11) 25 
Ending carrying value 22,640  22,338  21,409  26,684  24,724  22,640  24,724 
Other Invested Assets
Investment income 439  397  420  410  348  439  348 
Investment gains (losses) (11) 13  (167) (17) (11) (17)
Ending carrying value 19,479  19,656  18,755  18,202  18,097  19,479  18,097 
Total Investments
Investment income yield (1) 4.31  % 4.66  % 4.68  % 4.69  % 4.75  % 4.31  % 4.75  %
Investment fees and expenses yield (1) (0.14) % (0.12) % (0.11) % (0.13) % (0.14) % (0.14) % (0.14) %
Net Investment Income Yield (1) 4.17  % 4.54  % 4.57  % 4.56  % 4.61  % 4.17  % 4.61  %
Investment income $ 4,763  $ 5,171  $ 5,177  $ 5,191  $ 5,225  $ 4,763  $ 5,225 
Investment fees and expenses (157) (131) (121) (144) (157) (157) (157)
Net investment income including divested businesses 4,606  5,040  5,056  5,047  5,068  4,606  5,068 
Less: Net investment income from divested businesses —  —  —  —  —  —  — 
Adjusted Net Investment Income (8) $ 4,606  $ 5,040  $ 5,056  $ 5,047  $ 5,068  $ 4,606  $ 5,068 
Ending Carrying Value $ 451,238  $ 449,556  $ 434,196  $ 449,506  $ 442,971  $ 451,238  $ 442,971 
Investment Portfolio Gains (Losses) (9) $ (691) $ (874) $ (871) $ (240) $ (146) $ (691) $ (146)
Gross investment gains 433  271  119  292  331  433  331 
Gross investment losses (936) (276) (418) (465) (435) (936) (435)
Net credit loss (provision) release and (impairments) (188) (869) (572) (67) (42) (188) (42)
Investment Portfolio Gains (Losses) (9) (691) (874) (871) (240) (146) (691) (146)
Investment portfolio gains (losses) income tax (expense) benefit 181  188  155  80  41  181  41 
Investment Portfolio Gains (Losses), Net of Income Tax $ (510) $ (686) $ (716) $ (160) $ (105) $ (510) $ (105)
Derivative gains (losses) (9) (372) (1,278) (1,454) (123) (1,175) (372) (1,175)
Derivative gains (losses) income tax (expense) benefit 47  320  397  (45) 304  47  304 
Derivative Gains (Losses), Net of Income Tax $ (325) $ (958) $ (1,057) $ (168) $ (871) $ (325) $ (871)
See footnotes on Page 29.

26

INVESTMENTS
 
SUMMARY OF FIXED MATURITY SECURITIES AVAILABLE-FOR-SALE
BY SECTOR AND QUALITY DISTRIBUTION
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Unaudited (In millions, except ratios) Amount % of Total Amount % of Total Amount % of Total Amount % of Total Amount % of Total
U.S. corporate $ 82,482  29.1  % $ 82,523  29.1  % $ 78,552  28.9  % $ 80,717  28.7  % $ 80,553  28.9  %
Foreign corporate 54,285  19.1  % 53,690  18.9  % 51,377  19.0  % 55,444  19.7  % 54,029  19.4  %
Foreign government 48,111  16.9  % 45,994  16.2  % 42,685  15.8  % 45,489  16.2  % 42,793  15.4  %
U.S. government and agency 32,878  11.6  % 33,129  11.7  % 31,729  11.7  % 32,252  11.5  % 31,848  11.4  %
Residential mortgage-backed 26,543  9.4  % 28,458  10.0  % 27,785  10.3  % 29,096  10.3  % 31,142  11.2  %
Asset-backed securities and collateralized loan obligations 16,970  6.0  % 17,480  6.2  % 17,412  6.4  % 17,294  6.1  % 17,468  6.3  %
Municipals 12,597  4.4  % 12,324  4.3  % 11,347  4.2  % 11,171  4.0  % 10,938  3.9  %
Commercial mortgage-backed 9,988  3.5  % 10,259  3.6  % 10,095  3.7  % 9,949  3.5  % 9,638  3.5  %
Fixed Maturity Securities Available-For-Sale $ 283,854  100.0  % $ 283,857  100.0  % $ 270,982  100.0  % $ 281,412  100.0  % $ 278,409  100.0  %
NRSRO NAIC
RATING DESIGNATION
Aaa / Aa / A 1 $ 195,535  69.0  % $ 196,361  69.3  % $ 186,834  69.0  % $ 194,722  69.2  % $ 192,127  69.0  %
Baa 2 74,661  26.3  % 73,827  26.0  % 71,043  26.2  % 73,680  26.2  % 73,367  26.4  %
Ba 3 10,856  3.8  % 10,885  3.8  % 10,325  3.8  % 10,299  3.7  % 10,323  3.7  %
B 4 2,296  0.8  % 2,311  0.8  % 2,343  0.9  % 2,371  0.8  % 2,259  0.8  %
Caa and lower 5 395  0.1  % 346  0.1  % 338  0.1  % 258  0.1  % 267  0.1  %
In or near default 6 111  —  % 127  —  % 99  —  % 82  —  % 66  —  %
Total Fixed Maturity Securities Available-For-Sale (10) $ 283,854  100.0  % $ 283,857  100.0  % $ 270,982  100.0  % $ 281,412  100.0  % $ 278,409  100.0  %
GROSS UNREALIZED GAINS AND LOSSES
FIXED MATURITY SECURITIES AVAILABLE-FOR-SALE
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Gross unrealized gains $ 6,554  $ 5,991  $ 3,685  $ 6,876  $ 6,021 
Gross unrealized losses 27,469  28,982  38,702  25,835  28,122 
Net Unrealized Gains (Losses) $ (20,915) $ (22,991) $ (35,017) $ (18,959) $ (22,101)
See footnotes on Page 29.

27

INVESTMENTS
SUMMARY OF NET MORTGAGE LOANS (5)
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
              
Commercial mortgage loans $ 53,697  $ 52,737  $ 52,053  $ 52,111  $ 51,527 
Agricultural mortgage loans 19,361  19,579  19,658  19,559  19,461 
Residential mortgage loans 13,206  13,129  12,986  13,096  13,201 
Total 86,264  85,445  84,697  84,766  84,189 
Allowance for credit loss (692) (651) (639) (648) (737)
Net Mortgage Loans $ 85,572  $ 84,794  $ 84,058  $ 84,118  $ 83,452 
SUMMARY OF NET COMMERCIAL MORTGAGE LOANS
BY REGION AND PROPERTY TYPE (5)
 
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Unaudited (In millions, except ratios) Amount % of Total Amount % of Total Amount % of Total Amount % of Total Amount % of Total
Pacific $ 9,736  18.1  % $ 9,171  17.4  % $ 9,206  17.7  % $ 9,016  17.3  % $ 9,036  17.5  %
Non-U.S. 9,383  17.5  % 9,243  17.5  % 8,682  16.7  % 8,933  17.1  % 8,453  16.4  %
Middle Atlantic 7,647  14.2  % 7,572  14.4  % 7,581  14.6  % 7,477  14.3  % 7,430  14.4  %
South Atlantic 6,671  12.4  % 6,514  12.4  % 6,581  12.6  % 6,637  12.7  % 6,802  13.2  %
West South Central 3,765  7.0  % 3,496  6.6  % 3,417  6.6  % 3,472  6.7  % 3,502  6.8  %
New England 2,876  5.4  % 2,878  5.5  % 2,875  5.5  % 2,859  5.5  % 2,821  5.5  %
Mountain 2,284  4.3  % 2,227  4.2  % 2,191  4.2  % 2,193  4.2  % 2,192  4.3  %
East North Central 1,768  3.3  % 1,809  3.4  % 1,855  3.6  % 1,822  3.5  % 1,701  3.3  %
East South Central 624  1.2  % 623  1.2  % 622  1.2  % 654  1.3  % 653  1.3  %
West North Central 596  1.1  % 602  1.1  % 643  1.2  % 613  1.2  % 644  1.2  %
Multi-Region and Other 8,347  15.5  % 8,602  16.3  % 8,400  16.1  % 8,435  16.2  % 8,293  16.1  %
Total $ 53,697  100.0  % $ 52,737  100.0  % $ 52,053  100.0  % $ 52,111  100.0  % $ 51,527  100.0  %
Office $ 21,134  39.4  % $ 20,215  38.3  % $ 19,619  37.7  % $ 19,651  37.7  % $ 19,369  37.6  %
Apartment 11,357  21.2  % 11,928  22.6  % 11,807  22.7  % 11,974  23.0  % 11,353  22.0  %
Retail 8,289  15.4  % 7,433  14.1  % 7,441  14.3  % 7,218  13.9  % 7,371  14.3  %
Industrial 5,219  9.7  % 5,158  9.8  % 5,248  10.1  % 5,275  10.1  % 5,315  10.3  %
Single Family Rental 4,457  8.3  % 4,711  8.9  % 4,735  9.1  % 4,728  9.1  % 4,823  9.4  %
Hotel 3,117  5.8  % 3,170  6.0  % 3,088  5.9  % 3,140  6.0  % 3,199  6.2  %
Other 124  0.2  % 122  0.3  % 115  0.2  % 125  0.2  % 97  0.2  %
Total $ 53,697  100.0  % $ 52,737  100.0  % $ 52,053  100.0  % $ 52,111  100.0  % $ 51,527  100.0  %
See footnotes on Page 29.
28

INVESTMENTS
FOOTNOTES
(1)We calculate annualized yields using adjusted net investment income as a percent of average quarterly asset carrying values. Adjusted net investment income excludes realized gains and losses from sales and disposals, includes the impact of changes in foreign currency exchange rates and reflects the adjustments described on Page A-7 and presented on Page A-1. Asset carrying values utilized in the calculation of yields exclude unrecognized unrealized gains (losses), mortgage loans originated for third parties, collateral received in connection with our securities lending program, annuities funding structured settlement claims, freestanding derivative assets, collateral received from derivative counterparties and contractholder-directed equity securities. Invested assets reclassified to held-for-sale and ceded policy loans are included in the calculation of yields, but are otherwise excluded from asset carrying values. A yield is not presented for other invested assets, as it is not considered a meaningful measure of performance for this asset class.
(2)Fixed maturity securities includes investment income related to fair value option securities of $48 million, $50 million, ($17) million, $107 million, and $85 million for the three months ended March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, respectively, and $48 million and $85 million for the year-to-date period ended March 31, 2023 and March 31, 2024, respectively.
(3)Investment income from fixed maturity securities and net mortgage loans includes prepayment fees.
(4)The following table presents the components of total fixed maturity securities and a reconciliation to ending carrying value presented for fixed maturity securities.
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Fixed maturity securities available-for-sale $ 283,854  $ 283,857  $ 270,982  $ 281,412  $ 278,409 
Contractholder-directed equity securities and fair value option securities 10,063  10,204  9,680  10,331  10,313 
Total fixed maturity securities 293,917  294,061  280,662  291,743  288,722 
Less: Contractholder-directed equity securities 8,520  8,617  8,206  8,882  8,867 
Fixed maturity securities $ 285,397  $ 285,444  $ 272,456  $ 282,861  $ 279,855 
(5)Net mortgage loans exclude mortgage loans originated for third parties of $8,265 million, $8,238 million, $8,461 million and $8,083 million at amortized cost, which is primarily comprised of commercial mortgage loans of $8,022 million, $7,998 million, $8,215 million and $7,832 million at amortized cost, and does not include the related allowance for credit loss of $73 million, $66 million, $73 million and $77 million at June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, respectively. Prior to the second quarter of 2023, these mortgage loans originated for third parties were accounted for by MetLife as sales of portions of the related mortgage loans.
(6)Other limited partnership interests includes investment income related to private equity investments of $17 million, $223 million, $203 million, ($2) million and $301 million for the three months ended March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, respectively, and $17 million and $301 million for the year-to-date period ended March 31, 2023 and March 31, 2024, respectively. The annualized yields for these periods were 0.48%, 6.19%, 5.50%, (0.06%), 8.29%, 0.48% and 8.29%, respectively.
(7)Other limited partnership interests includes ending carrying value related to private equity investments of $14,225 million, $14,608 million, $14,862 million, $14,738 million and $14,276 million, at March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, respectively.
(8)Adjusted net investment income reflects the adjustments as presented on Page 5.
(9)Investment portfolio gains (losses) and Derivative gains (losses) reflect the non-GAAP adjustments as presented below:
For the Three Months Ended For the Year-to-Date Period Ended
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Net investment gains (losses) $ (684) $ (1,039) $ (927) $ (174) $ (375) $ (684) $ (375)
Less: Non-investment portfolio gains (losses) 13  (95) (63) 64  (226) 13  (226)
Less: Provision for credit loss on certain mortgage loans originated for third parties —  (73) (7) (4) —  (4)
Less: Other adjustments (6) —  (6)
Investment portfolio gains (losses) $ (691) $ (874) $ (871) $ (240) $ (146) $ (691) $ (146)
For the Three Months Ended For the Year-to-Date Period Ended
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Net derivative gains (losses) $ (90) $ (997) $ (1,202) $ 149  $ (979) $ (90) $ (979)
Less: Investment hedge adjustments 264  263  232  253  176  264  176 
Less: Other adjustments 18  18  20  19  20  18  20 
Derivative gains (losses) $ (372) $ (1,278) $ (1,454) $ (123) $ (1,175) $ (372) $ (1,175)
(10)Fixed maturity securities available-for-sale are presented by NRSRO rating and the applicable NAIC designation from the NAIC published comparison of NRSRO ratings to NAIC designations, except for (i) non-agency residential mortgage-backed securities (“RMBS”) and commercial mortgage-backed securities (“CMBS”) and (ii) securities rated Ca or C by NRSROs that are designated NAIC 6. NRSRO ratings are based on availability of applicable ratings. If no NRSRO rating is available, then an internally developed rating is used. Over time, credit ratings can migrate, up or down, through the NRSRO's and NAIC's continuous monitoring process. Amounts presented for non-agency RMBS and CMBS are presented using NAIC designations for modeled securities. The NAIC evaluates non-agency RMBS and CMBS held by insurers on an annual basis. When we acquire non-agency RMBS and CMBS that have not been previously evaluated by the NAIC, an internally developed designation is used until a NAIC designation becomes available. NAIC designations are generally similar to the credit quality ratings of the NRSRO, except for (i) non-agency RMBS and CMBS and (ii) securities rated Ca or C by NRSROs that are designated NAIC 6; accordingly, NAIC designations may not correspond to NRSRO ratings.
29

imagk05a.jpg
Appendix






APPENDIX
METLIFE
RECONCILIATION DETAIL
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Reconciliation to Adjusted Earnings Available to Common Shareholders
Net income (loss) available to MetLife, Inc.'s common shareholders $ 14  $ 370  $ 422  $ 574  $ 800  $ 14  $ 800 
Add: Preferred stock dividends 66  32  67  33  67  66  67 
Add: Preferred stock redemption premium —  —  —  —  —  —  — 
Add: Net income (loss) attributable to noncontrolling interests
Net income (loss) 85  408  495  614  875  $ 85  $ 875 
Less: adjustments from net income (loss) to adjusted earnings:
Net investment gains (losses) (684) (1,039) (927) (174) (375) (684) (375)
Net derivative gains (losses) (90) (997) (1,202) 149  (979) (90) (979)
Market risk benefit remeasurement gains (losses) (188) 817  796  (431) 694  (188) 694 
Premiums - Divested businesses
—  —  —  —  —  —  — 
Universal life and investment-type product policy fees - Divested businesses
—  —  —  —  —  —  — 
Net investment income
Investment hedge adjustments (264) (263) (232) (253) (176) (264) (176)
Unit-linked contract income 303  296  580  542  303  542 
Other adjustments —  (1) (3) (8) — 
Divested businesses —  —  —  —  —  —  — 
Other revenues
Asymmetrical and non-economic accounting —  —  —  29  39  —  39 
Other adjustments (3) (7) (11) (13) (12) (3) (12)
Divested businesses —  —  —  —  —  —  — 
Policyholder benefits and claims and policyholder dividends
Asymmetrical and non-economic accounting (84) (74) (26) (14) (84) (14)
Market volatility 14  44  64  62  67  14  67 
Divested businesses —  —  —  —  —  —  — 
Policyholder liability remeasurement (gains) losses - Divested businesses
—  —  —  —  —  —  — 
Interest credited to policyholder account balances
Asymmetrical and non-economic accounting (19) 10  44  (103) (24) (19) (24)
Unit-linked contract costs (303) (301) (582) (539) (303) (539)
Divested businesses —  —  —  —  —  —  — 
Capitalization of DAC - Divested businesses
—  —  —  —  —  —  — 
Amortization of DAC and VOBA - Divested businesses
—  —  —  —  —  —  — 
Amortization of negative VOBA - Divested business
—  —  —  —  —  —  — 
Interest expense on debt - Divested business
—  —  —  —  —  —  — 
Other expenses
Other adjustments (16) (11) (21) (7) (7) (16) (7)
Divested businesses (11) (9) (9) (9) (4) (11) (4)
Goodwill impairment —  —  —  —  —  —  — 
Provision for income tax (expense) benefit 180  419  429  260  180  260 
Adjusted earnings 1,250  1,524  1,555  1,394  1,401  1,250  1,401 
Less: Preferred stock dividends 66  32  67  33  67  66  67 
Adjusted earnings available to common shareholders $ 1,184  $ 1,492  $ 1,488  $ 1,361  $ 1,334  $ 1,184  $ 1,334 
A-1

APPENDIX
METLIFE
NOTABLE ITEMS (1)
METLIFE TOTAL
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 14  $ —  $ —  $ —  $ — 
Litigation reserves and settlement costs —  —  —  (76) —  —  — 
Total notable items $ —  $ —  $ 14  $ (76) $ —  $ —  $ — 
GROUP BENEFITS
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 27  $ —  $ —  $ —  $ — 
Total notable items $ —  $ —  $ 27  $ —  $ —  $ —  $ — 
RIS
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments $ —  $ —  $ 61  $ —  $ —  $ —  $ — 
Total notable items $ —  $ —  $ 61  $ —  $ —  $ —  $ — 
(1)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results.
A-2

APPENDIX
METLIFE
NOTABLE ITEMS (1) CONTINUED
ASIA
   For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ (94) $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ (94) $ —  $ —  $ —  $ — 
LATIN AMERICA
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ —  $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ —  $ —  $ —  $ —  $ — 
EMEA
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ 18  $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ 18  $ —  $ —  $ —  $ — 
METLIFE HOLDINGS
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Actuarial assumption review and other insurance adjustments
$ —  $ —  $ $ —  $ —  $ —  $ — 
Total notable items
$ —  $ —  $ $ —  $ —  $ —  $ — 
CORPORATE & OTHER
  
For the Three Months Ended For the Year-to-Date Period Ended
Unaudited (In millions)
March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024 March 31, 2023 March 31, 2024
Litigation reserves and settlement costs —  —  —  (76) —  —  — 
Total notable items $ —  $ —  $ —  $ (76) $ —  $ —  $ — 
(1)These notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results.
A-3

APPENDIX
METLIFE
EQUITY DETAILS, BOOK VALUE DETAILS AND RETURN ON EQUITY
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Total MetLife, Inc.'s stockholders' equity $ 32,194  $ 30,261  $ 25,658  $ 30,015  $ 28,535 
Less: Preferred stock 3,818  3,818  3,818  3,818  3,818 
MetLife, Inc.'s common stockholders' equity 28,376  26,443  21,840  26,197  24,717 
Less: Net unrealized investment gains (losses), net of income tax (14,606) (16,800) (26,548) (14,323) (16,611)
  Future policy benefits discount rate remeasurement gains (losses), net of income tax 2,748  3,919  10,245  2,658  4,773 
  Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 186  108  (4) 27  (47)
  Defined benefit plans adjustment, net of income tax (1,356) (1,331) (1,308) (1,446) (1,421)
Total MetLife, Inc.'s common stockholders' equity, excluding AOCI other than FCTA 41,404  40,547  39,455  39,281  38,023 
Less: Accumulated year-to-date total notable items (2) —  —  14  (62) — 
Total MetLife, Inc.'s common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 41,404  $ 40,547  $ 39,441  $ 39,343  $ 38,023 
Unaudited (In millions, except per share data) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Book value per common share $ 36.89  $ 34.92  $ 29.34  $ 35.85  $ 34.54 
Less: Net unrealized investment gains (losses), net of income tax (18.99) (22.19) (35.66) (19.60) (23.21)
  Future policy benefits discount rate remeasurement gains (losses), net of income tax 3.57  5.18  13.77  3.64  6.68 
  Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax 0.24  0.14  (0.01) 0.04  (0.07)
  Defined benefit plans adjustment, net of income tax (1.76) (1.76) (1.76) (1.98) (1.99)
Book value per common share, excluding AOCI other than FCTA $ 53.83  $ 53.55  $ 53.00  $ 53.75  $ 53.13 
Common shares outstanding, end of period 769.2  757.2  744.4  730.8  715.7 
For the Three Months Ended (1)
Unaudited (In millions, except ratios) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
Return on MetLife, Inc.'s:
Common stockholders' equity 0.2  % 5.4  % 7.0  % 9.6  % 12.6  %
Adjusted return on MetLife, Inc.'s:
Common stockholders' equity 17.4  % 21.8  % 24.7  % 22.7  % 21.0  %
Common stockholders' equity, excluding AOCI other than FCTA 11.3  % 14.6  % 14.9  % 13.8  % 13.8  %
Common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) 11.3  % 14.6  % 14.7  % 14.6  % 13.8  %
Average common stockholders' equity $ 27,220  $ 27,410  $ 24,142  $ 24,019  $ 25,457 
Average common stockholders' equity, excluding AOCI other than FCTA $ 41,856  $ 40,976  $ 40,001  $ 39,368  $ 38,652 
Average common stockholders' equity, excluding total notable items (excludes AOCI other than FCTA) (2) $ 41,856  $ 40,976  $ 39,994  $ 39,392  $ 38,652 
(1) Annualized using quarter-to-date results.
(2)Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items can affect MetLife’s results either positively or negatively. See Page A-2 for further detail.
A-4

APPENDIX
METLIFE
ADJUSTED PREMIUMS, FEES AND OTHER REVENUES, OTHER EXPENSES AND ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS - CONSTANT CURRENCY BASIS
 ADJUSTED PREMIUMS, FEES AND OTHER REVENUES, ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
GROUP BENEFITS (1) $ 6,049  $ 6,013  $ 5,866  $ 6,001  $ 6,330 
RIS (1) 648  2,823  2,478  2,883  813 
ASIA 1,659  1,645  1,712  1,697  1,744 
LATIN AMERICA 1,380  1,353  1,440  1,489  1,496 
EMEA 568  565  579  593  620 
METLIFE HOLDINGS (1) 959  938  910  901  841 
CORPORATE & OTHER (1) 117  126  112  100  104 
Adjusted premiums, fees and other revenues, on a constant currency basis $ 11,380  $ 13,463  $ 13,097  $ 13,664  $ 11,948 
Adjusted premiums, fees and other revenues $ 11,520  $ 13,594  $ 13,181  $ 13,671  $ 11,948 
ASIA (including operating joint ventures) (2), (3) $ 2,140  $ 2,056  $ 2,139  $ 2,064  $ 2,272 
 OTHER EXPENSES ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
GROUP BENEFITS (1) $ 932  $ 950  $ 937  $ 977  $ 1,003 
RIS (1) 146  146  138  135  172 
ASIA 740  735  772  779  744 
LATIN AMERICA 443  459  483  526  512 
EMEA 291  302  310  329  332 
METLIFE HOLDINGS (1) 238  231  238  220  223 
CORPORATE & OTHER (1) 177  229  250  290  194 
Adjusted other expenses on a constant currency basis $ 2,967  $ 3,052  $ 3,128  $ 3,256  $ 3,180 
Adjusted other expenses $ 3,030  $ 3,113  $ 3,159  $ 3,261  $ 3,180 
ASIA (including operating joint ventures) (2), (4) $ 864  $ 851  $ 886  $ 877  $ 860 
 ADJUSTED EARNINGS AVAILABLE TO COMMON SHAREHOLDERS ON A CONSTANT CURRENCY BASIS
For the Three Months Ended
Unaudited (In millions) March 31, 2023 June 30, 2023 September 30, 2023 December 31, 2023 March 31, 2024
GROUP BENEFITS (1) $ 307  $ 372  $ 510  $ 466  $ 284 
RIS (1) 400  417  470  421  399 
ASIA 269  422  273  296  423 
LATIN AMERICA 221  213  194  206  233 
EMEA 57  66  87  48  77 
METLIFE HOLDINGS (1) 158  211  208  156  159 
CORPORATE & OTHER (1) (236) (228) (262) (232) (241)
Adjusted earnings available to common shareholders on a constant currency basis $ 1,176  $ 1,473  $ 1,480  $ 1,361  $ 1,334 
Adjusted earnings available to common shareholders $ 1,184  $ 1,492  $ 1,488  $ 1,361  $ 1,334 
(1) Amounts on a reported basis, as constant currency impact is not significant.
(2) Adjusted premiums, fees and other revenues as well as other expenses are reported as part of net investment income on the statements of adjusted earnings available to common shareholders on Page 15 for operating joint ventures.
(3) Includes MetLife, Inc.'s share of adjusted premiums, fees and other revenues for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
(4) Includes MetLife, Inc.'s share of adjusted other expenses for operating joint ventures in: (i) China, (ii) India, (iii) Malaysia and (iv) Vietnam, on the basis of proportional consolidation and MetLife's percentage ownership. These operating joint ventures are accounted for using the equity method of accounting under GAAP.
A-5

APPENDIX
METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES

In this QFS, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of our business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
Non-GAAP financial measures: Comparable GAAP financial measures:
(i) total adjusted revenues (i) total revenues
(ii) total adjusted expenses (ii) total expenses
(iii) adjusted premiums, fees and other revenues (iii) premiums, fees and other revenues
(iv) adjusted premiums, fees and other revenues, excluding PRT (iv) premiums, fees and other revenues
(v) adjusted net investment income (v) net investment income
(vi) adjusted earnings (vi) net income (loss)
(vii) adjusted earnings available to common shareholders (vii) net income (loss) available to MetLife, Inc.’s common shareholders
(viii) adjusted earnings available to common shareholders, excluding total notable items (viii) net income (loss) available to MetLife, Inc.’s common shareholders
(ix) adjusted earnings available to common shareholders per diluted common share (ix) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share
(x) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share (x) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share
(xi) adjusted return on equity (xi) return on equity
(xii) adjusted return on equity, excluding AOCI other than FCTA (xii) return on equity
(xiii) adjusted return on equity, excluding total notable items (excludes AOCI other than FCTA) (xiii) return on equity
(xiv) investment portfolio gains (losses) (xiv) net investment gains (losses)
(xv) derivative gains (losses) (xv) net derivative gains (losses)
(xvi) adjusted capitalization of DAC (xvi) capitalization of DAC
(xvii) total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA (xvii) total MetLife, Inc.’s stockholders’ equity
(xviii) total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA) (xviii) total MetLife, Inc.’s stockholders’ equity
(xix) book value per common share, excluding AOCI other than FCTA (xix) book value per common share
(xx) adjusted other expenses (xx) other expenses
(xxi) adjusted other expenses, net of adjusted capitalization of DAC (xxi) other expenses, net of capitalization of DAC
(xxii) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses (xxii) other expenses, net of capitalization of DAC
(xxiii) adjusted expense ratio (xxiii) expense ratio
(xxiv) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT (xxiv) expense ratio
(xxv) direct expenses (xxv) other expenses
(xxvi) direct expenses, excluding total notable items related to direct expenses (xxvi) other expenses
(xxvii) direct expense ratio (xxvii) expense ratio
(xxviii) direct expense ratio, excluding total notable items related to direct expenses and PRT (xxviii) expense ratio
(xxix) future policy benefits at original discount rate (xxix) future policy benefits at balance sheet discount rate
Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period. As a result, comparable prior period amounts are updated each period to reflect the most recent period average foreign currency exchange rates.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this QFS and in this period’s earnings news release, which is available at www.metlife.com.

A-6

APPENDIX
METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES (CONTINUED)
Our definitions of non-GAAP and other financial measures discussed in this QFS may differ from those used by other companies:

Adjusted earnings and related measures
adjusted earnings;
adjusted earnings available to common shareholders;
adjusted earnings available to common shareholders, excluding total notable items;
adjusted earnings available to common shareholders per diluted common share;
adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
adjusted earnings available to common shareholders on a constant currency basis.
These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.
Adjusted revenues and adjusted expenses
These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.

Market volatility can have a significant impact on MetLife’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.
Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.
Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.
Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.
Other adjustments are made to the line items indicated in calculating adjusted earnings:
Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs").
Other revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives.
Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.
Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders.
A-7


APPENDIX
METLIFE
NON-GAAP AND OTHER FINANCIAL DISCLOSURES (CONTINUED)
Investment portfolio gains (losses) and derivative gains (losses)
These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).
Return on equity and related measures
Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.
Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, and total notable items, net of income tax.
Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.'s average common stockholders’ equity.
Adjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity.
Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity, excluding AOCI other than FCTA.
Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA).
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses.
Expense ratio, direct expense ratio, adjusted expense ratio and related measures
Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
Direct expense ratio: adjusted direct expenses divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses.
Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
Asia general account assets under management and related measures
Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.

Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.
Other items
The following additional information is relevant to an understanding of our performance results:
Statistical sales information for Latin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group). Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.
A-8

APPENDIX
METLIFE
ACRONYMS
 
AOCI Accumulated other comprehensive income (loss)
DAC Deferred policy acquisition costs
DPL Deferred profit liabilities
EMEA Europe, the Middle East and Africa
FCTA Foreign currency translation adjustments
GA General account
GA AUM General account assets under management
GAAP Accounting principles generally accepted in the United States of America
GICs Guaranteed interest contracts
NAIC National Association of Insurance Commissioners
NRSRO Nationally Recognized Statistical Rating Organization
PRT Pension risk transfers
QFS Quarterly financial supplement
RIS Retirement and Income Solutions
VOBA Value of business acquired
A-9


imagk05a.jpg
navigatinglifetogethera04.jpg

EX-99.3 4 ex993q12024totalaumfacts.htm EX-99.3 ex993q12024totalaumfacts
Assets Under Management March 31, 2024 Investors turn to MetLife Investment Management for our deep and long-established expertise in Public Fixed Income, Private Capital and Real Estate. Seeking to deliver strong, risk-adjusted returns, we create tailored portfolio solutions by listening first, strategizing second, and collaborating constantly. We are institutional, but far from typical. Total Assets Under Management1 By Asset Type $593.7 Billion Mortgage Loans $107.4 Public Corporates $105.1 Structured Products $67.5 Private Corporates $56.4 U.S. Government and Agency $49.8 Foreign Government $37.8 Private Infrastructure $34.3 Cash and Short-Term Investments $28.6 Real Estate Equity $24.2 Common and Preferred Equity $19.2 Alternatives $17.2 Municipals $13.9 Emerging Market Debt $12.8 Private Structured Credit $6.8 Bank Loans $6.2 High Yield $4.9 Middle Market Private Capital $1.6 Institutional Client Assets Under Management1 $177.3 Billion Insurance/Financial $81.9 Sub-Advisory $37.2 Corporate $29.6 Public $13.5 Commingled Fund2 $12.5 Other3 $2.6 1 As of March 31, 2024. At estimated fair value. Dollars in billions. Cash and Short-Term Investments includes cash equivalents. See Explanatory Note. 2 Includes limited partnerships, collective trusts, mutual funds registered under the Investment Company Act and other vehicles offered or available to qualifying investors, including third parties and affiliates. 3 Includes non-profit clients, Taft-Hartley pension fund clients and asset manager clients. 440 Mandates Representative Capabilities Private Capital Corporate Private Credit Infrastructure Debt Private Structured Credit Middle Market Private Capital Residential Whole Loans Private Equity Public Fixed Income Bank Loans Core Core Plus Corporate Emerging Market Debt High Yield Long Duration Multi-Sector Short Duration Stable Value Real Estate Commercial Mortgage Loans Real Estate Equity Index Strategies Insurance Advisory Liability Driven Investing (LDI) 43% 17% 17% 11% 5% 7% Mandates Profile Institutional Client AUM investments.metlife.com Exhibit 99.3


 
Explanatory Note The following information is relevant to an understanding of our assets under management ("AUM") managed by MetLife Investment Management, LLC and certain of its affiliates ("MIM"). MIM is MetLife, Inc.'s institutional investment management business. Our definitions may differ from those used by other companies. Total Assets Under Management (“Total AUM”) is comprised of GA AUM plus Institutional Client AUM (each, as defined below). General Account AUM (“GA AUM”) is used by MetLife to describe assets in its general account ("GA") investment portfolio. GA AUM is stated at estimated fair value and is comprised of GA total investments, the portion of the GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties (“net mortgage loans”) (including commercial (“net commercial mortgage loans”), agricultural (“net agricultural mortgage loans”) and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. Classification of GA AUM by sector is based on the nature and characteristics of the underlying investments which can vary from how they are classified under GAAP. Accordingly, the underlying investments within certain real estate and real estate joint ventures that are primarily net commercial mortgage loans (at net asset value, net of deduction for encumbering debt) have been reclassified to exclude them from real estate equity and include them as net commercial mortgage loans. Institutional Client AUM is comprised of SA AUM plus TP AUM (each, as defined below). MIM manages Institutional Client AUM in accordance with client guidelines contained in each investment advisory agreement (“Mandates”). Separate Account AUM (“SA AUM”) is comprised of separate account investment portfolios of MetLife insurance companies, which are managed by MIM and included in MetLife, Inc.’s consolidated financial statements at estimated fair value. Third Party AUM (“TP AUM”) is comprised of non-proprietary assets managed by MIM on behalf of unaffiliated/third party clients, which are stated at estimated fair value. Such non-proprietary assets are owned by unaffiliated/third-party clients and, accordingly, are generally not included in MetLife, Inc.’s consolidated financial statements. Additional information about MetLife’s general account investment portfolio is available in MetLife, Inc.’s quarterly financial materials for the quarter ended March 31, 2024, which may be accessed through MetLife’s Investor Relations web page at https://investor.metlife.com. Neither MetLife, Inc.’s quarterly financial materials, nor any other information from the MetLife website, is a part of or incorporated by reference into this Total AUM Fact Sheet. L0823033927[exp0824][All States] One MetLife Way | Whippany, New Jersey 07981 © 2023 METLIFE, INC.


 
EX-99.4 5 ex9941q24supplementalsli.htm EX-99.4 ex9941q24supplementalsli
1Q24 Supplemental Slides1 John McCallion Chief Financial Officer and Head of MetLife Investment Management Exhibit 99.4 1 These slides highlight information in MetLife, Inc.'s earnings release, quarterly financial supplement and other prior public disclosures.


 
2 Table of contents Topic Page No. Net income (loss) to adjusted earnings 3 Adjusted earnings, ex. total notable items, by segment 4 Variable investment income (VII) 5 Investments 7 Direct expense ratio 8 Cash & capital 9 Appendix 10


 
3 Net income (loss) to adjusted earnings 1Q24 (post-tax) $ in millions $ per share1 Net Income (Loss) $800 $1.10 Less: Net Investment Gains (Losses) (296) (0.41) Net Derivative Gains (Losses) (773) (1.06) Market Risk Benefit Remeasurement Gains (Losses) 548 0.75 Investment Hedge Adjustments (139) (0.19) Other 126 0.17 Adjusted Earnings $1,334 $1.83 1 The per share data for each item is calculated on a standalone basis and may not sum to the total.


 
4 ($ in millions - except per share data) 1Q24 1Q23 % Change % Change (Constant Rate) Key Drivers1 Favorable Unfavorable Group Benefits $284 $307 (7%) Underwriting Margins Retirement and Income Solutions 399 400 —% Investment Margins Underwriting Margins Asia 423 280 51% 57% Investment Margins; Underwriting Margins; Tax Items Latin America 233 215 8% 5% Equity Markets; Volume Growth; Underwriting Margins EMEA 77 60 28% 35% Underwriting Margins; Volume Growth; Investment Margins Expense Margins MetLife Holdings 159 158 1% Investment Margins Foregone earnings2 Corporate & Other (241) (236) Investment Margins Interest on Debt; Taxes Adjusted Earnings ex. Total Notable Items $1,334 $1,184 13% 13% Adjusted EPS ex. Total Notable Items $1.83 $1.52 20% 21% Adjusted earnings, ex. total notable items, by segment 1 To be discussed on MetLife, Inc.'s first quarter 2024 earnings conference call and audio webcast. 2 As a result of the reinsurance transaction with Global Atlantic Financial Group being effective in November 2023.


 
5 ($44) $221 $179 $63 $260 1Q23 2Q23 3Q23 4Q23 1Q24 1Q24 VII driven by higher private equity returns1 ($ in millions - pre-tax) Private Equity Other 1 Quarterly target VII range of $375 million, based on full year 2024 guidance range of ~ $1.5 billion. $0


 
6 ($ in millions - post-tax1) 1Q23 2Q23 3Q23 4Q23 1Q24 Group Benefits $— $4 $1 $1 $4 Retirement and Income Solutions (3) 29 35 23 73 Asia (25) 84 37 10 56 Latin America (2) 4 5 4 1 EMEA — — — — — MetLife Holdings 2 41 35 23 55 Corporate & Other (7) 13 28 (11) 16 Total Variable Investment Income $(35) $175 $141 $50 $205 1 Assumes a 21% U.S. statutory tax rate. VII by segment


 
7 FY21 FY22 FY23 1Q23 1Q24 Strong recurring income supported by higher interest rates and asset growth ($ in billions) Recurring income VII Net Investment Income1 $16.7 $5.7 Roll Off vs. Reinvestment $15.6 $1.5 New Money Yield Roll Off Yield 10-Year Treasury Yield 1Q21 3Q21 1Q22 3Q22 1Q23 3Q23 1Q24 1% 2% 3% 4% 5% 6% 7% 6.60% 5.57% 4.20% 1 As reported, on an adjusted basis. $21.3 $18.2 $4.6 $19.3 $0.4 $19.7 $4.7 $5.1 $0.3 $4.8


 
8 12.2% 11.9% FY23 1Q24 1 Direct expense ratio, excluding total notable items related to direct expenses and pension risk transfers (PRT). 12.3% Annual Target 1Q24 direct expense ratio1 of 11.9%, below 12.3% annual target


 
9 Holding Company Cash1 $4.2 $4.2 $4.9 $5.2 $5.2 1Q23 2Q23 3Q23 4Q23 1Q24 Cash & capital 1 Includes cash and liquid assets at MetLife, Inc. and other holding companies at quarter-end. 2 Includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company. MetLife calculates RBC annually as of December 31 and, accordingly, the calculation does not reflect conditions and factors occurring after the year end. 3 Includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company for both periods. $3.0B to $4.0B Cash Buffer Capital ($ in billions) • Share repurchases of $1.2 billion in 1Q24 – ~$330 million shares repurchased in April 2024 • 2023 Combined NAIC Risk-Based Capital ratio2 of 407%, above 360% target • Expected total U.S. Statutory Adjusted Capital3 of $18.3 billion at 3/31/24, down 6% from 12/31/23 • Expected Japan Solvency Margin ratio of ~725% at 3/31/24


 
Appendix


 
11 High quality commercial mortgage loan (CML) portfolio1 • Concentrated in high quality assets and in larger primary markets • 65% average Loan-to-Value (LTV) Ratio and 2.2x average Debt Service Coverage Ratio (DSCR) – 85% of CML portfolio with LTVs of 80% or less – 95% of CML portfolio with DSCRs of 1x or greater – 69% average office LTV ratio and 2.1x average DSCR 1At March 31,2024. All references to commercial mortgage loans in this earnings presentation are to net commercial mortgage loans, consisting of commercial mortgage loans, excluding commercial mortgage loans originated for third parties and related allowance for credit loss. LTV and DSCR Matrix $51.5 Billion LTV >1.2x 1.0-1.2x <1.0x Total <65% 47.7% 2.5% 1.2% 51.4% 65-75% 24.4% 1.8% 1.0% 27.2% 76-80% 5.2% 0.9% 0.6% 6.7% >80% 8.9% 3.3% 2.5% 14.7% Total 86.2% 8.5% 5.3% 100.0%


 
12 Cautionary Statement on Forward-Looking Statements The forward-looking statements in this presentation, using words such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms, are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements.


 
13 Explanatory Note on Non-GAAP and Other Financial Information Any references in this presentation (except in this Explanatory Note on Non-GAAP Financial Information and Reconciliations) to: Should be read as, respectively: (i) net income (loss); (i) net income (loss) available to MetLife, Inc.’s common shareholders; (ii) net income (loss) per share; (ii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (iii) adjusted earnings; and (iii) adjusted earnings available to common shareholders; and (iv) adjusted earnings per share. (iv) adjusted earnings available to common shareholders per diluted common share. In this presentation, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance the understanding for MetLife and its investors of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment. The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP: Non-GAAP financial measures: Comparable GAAP financial measures: (i) adjusted premiums, fees and other revenues; (i) premiums, fees and other revenues; (ii) adjusted premiums, fees and other revenues, excluding PRT; (ii) premiums, fees and other revenues; (iii) adjusted capitalization of deferred policy acquisition costs (DAC); (iii) capitalization of DAC; (iv) adjusted earnings available to common shareholders; (iv) net income (loss) available to MetLife, Inc.’s common shareholders; (v) adjusted earnings available to common shareholders, excluding total notable items; (v) net income (loss) available to MetLife, Inc.’s common shareholders; (vi) adjusted earnings available to common shareholders per diluted common share; (vi) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (vii) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share; (vii) net income (loss) available to MetLife, Inc.’s common shareholders per diluted common share; (viii) adjusted other expenses; (viii) other expenses; (ix) adjusted other expenses, net of adjusted capitalization of DAC; (ix) other expenses, net of capitalization of DAC; (x) adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses; (x) other expenses, net of capitalization of DAC; (xi) adjusted expense ratio; (xi) expense ratio; (xii) adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT; (xii) expense ratio; (xiii) direct expenses; (xiii) other expenses; (xiv) direct expenses, excluding total notable items related to direct expenses; (xiv) other expenses; (xv) direct expense ratio; (xv) expense ratio; (xvi) direct expense ratio, excluding total notable items related to direct expenses and PRT; and (xvi) expense ratio; and (xvii) free cash flows of all holding companies. (xvii) MeLife, Inc. (parent company) net cash provided by (used in) operating activities.


 
14 MetLife’s definitions of non-GAAP and other financial measures discussed in this presentation may differ from those used by other companies: Adjusted earnings and related measures • adjusted earnings; • adjusted earnings available to common shareholders; • adjusted earnings available to common shareholders, excluding total notable items; • adjusted earnings available to common shareholders per diluted common share; • adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and • adjusted earnings available to common shareholders on a constant currency basis. These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife’s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends. Adjusted revenues and adjusted expenses These financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP. Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments. Explanatory Note on Non-GAAP and Other Financial Information (Continued) Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the most recent period. As a result, comparable prior period amounts are updated each period to reflect the most recent period average foreign currency exchange rates. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this presentation and in this period’s earnings news release, which is available at www.metlife.com.


 
15 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments"). • Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance. • Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation- indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts. • Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance. Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Other adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities ("Unit-linked contract income") and ("Unit-linked contract costs"). • Other revenues include fee revenue on synthetic guaranteed interest contracts ("GICs") accounted for as freestanding derivatives. • Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements. • Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives. Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance. The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.’s common shareholders. Investment portfolio gains (losses) and derivative gains (losses) These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).


 
16 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Return on equity and related measures • Total MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, net of income tax. • Total MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): Total MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment components of AOCI, and total notable items, net of income tax. • Return on MetLife, Inc.’s common stockholders’ equity: net income (loss) available to MetLife, Inc.’s common shareholders divided by MetLife, Inc.'s average common stockholders’ equity. • Adjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity. • Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average common stockholders’ equity, excluding AOCI other than FCTA. • Adjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA). The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses. Expense ratio, direct expense ratio, adjusted expense ratio and related measures • Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues. • Direct expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses. • Direct expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT. • Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues. • Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT. General Account (GA) assets under management (GA AUM) GA AUM is used by MetLife to describe assets in its GA investment portfolio. GA AUM is stated at estimated fair value and is comprised of GA total investments, the portion of the GA investment portfolio classified within assets held-for-sale, and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties (“net mortgage loans”) (including commercial (“net commercial mortgage loans”), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. Classification of GA AUM by sector is based on the nature and characteristics of the underlying investments which can vary from how they are classified under GAAP. Accordingly, the underlying investments within certain real estate and real estate joint ventures that are primarily net commercial mortgage loans (at net asset value, net of deduction for encumbering debt) have been reclassified to exclude them from real estate equity and include them as net commercial mortgage loans. Asia GA AUM and related measures Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM. Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.


 
17 Explanatory Note on Non-GAAP and Other Financial Information (Continued) Statistical sales information: • Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products. • Retirement and Income Solutions: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance. • Latin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group). Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity. The following additional information is relevant to an understanding of MetLife’s performance results and outlook: • Volume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates. • MetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders. • Notable items reflect the unexpected impact of events that affect MetLife’s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders. • Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block. • We refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.


 
18 Reconciliation of Net Income (Loss) Available to MetLife, Inc.'s Common Shareholders to Adjusted Earnings Available to Common Shareholders 1Q24 1Q23 Earnings Per Weighted Average Common Share Diluted1 Earnings Per Weighted Average Common Share Diluted1 (In millions, except per share data) Net Income (loss) available to MetLife, Inc.'s common shareholders $ 800 $ 1.10 $ 14 $ 0.02 Adjustments from net income (loss) available to MetLife, Inc.'s common shareholders to adjusted earnings available to common shareholders: Less: Net investment gains (losses) (375) (0.51) (684) (0.88) Less: Net derivative gains (losses) (979) (1.34) (90) (0.12) Less: Market risk benefit remeasurement gains (losses) 694 0.95 (188) (0.24) Less: Other adjustments to net income (loss) (126) (0.18) (383) (0.48) Less: Provision for income tax (expense) benefit 260 0.36 180 0.23 Add: Net income (loss) attributable to noncontrolling interests 8 0.01 5 0.01 Adjusted earnings available to common shareholders 1,334 1.83 1,184 1.52 Less: Total notable items — — — — Adjusted earnings available to common shareholders, excluding total notable items $ 1,334 1.83 $ 1,184 $ 1.52 Adjusted earnings available to common shareholders on a constant currency basis $ 1,334 $ 1.83 $ 1,176 $ 1.51 Adjusted earnings available to common shareholders, excluding total notable items, on a $ 1,334 $ 1.83 $ 1,176 $ 1.51 constant currency basis Weighted average common shares outstanding - diluted 728.4 781.2 1Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.


 
19 Reconciliation to Adjusted Earnings Available to Common Shareholders, Excluding Total Notable Items 1Q24 Group Benefits1 Retirement & Income Solutions1 Asia Latin America EMEA MetLife Holdings1 Corporate & Other1 (In millions) Adjusted earnings available to common shareholders $ 284 $ 399 $ 423 $ 233 $ 77 $ 159 $ (241) Less: Total notable items — — — — — — — Adjusted earnings available to common shareholders, excluding total notable items $ 284 $ 399 $ 423 $ 233 $ 77 $ 159 $ (241) Adjusted earnings available to common shareholders, on a constant currency basis $ 423 $ 233 $ 77 Adjusted earnings available to common shareholders, excluding total notable items on a constant currency basis $ 423 $ 233 $ 77 1Q23 Group Benefits1 Retirement & Income Solutions1 Asia Latin America EMEA MetLife Holdings1 Corporate & Other1 (In millions) Adjusted earnings available to common shareholders $ 307 $ 400 $ 280 $ 215 $ 60 $ 158 $ (236) Less: Total notable items — — — — — — — Adjusted earnings available to common shareholders, excluding total notable items $ 307 $ 400 $ 280 $ 215 $ 60 $ 158 $ (236) Adjusted earnings available to common shareholders, on a constant currency basis $ 269 $ 221 $ 57 Adjusted earnings available to common shareholders, excluding total notable items on a constant currency basis $ 269 $ 221 $ 57 1Results on a constant currency basis are not included as constant currency impact is not significant.


 
20 Reconciliation of Net Investment Income to Adjusted Net Investment Income FY21 FY22 FY23 1Q23 1Q24 (In millions) Net investment income $ 21,395 $ 15,916 $ 19,908 $ 4,645 $ 5,436 Less: Adjustments to net investment income Investment hedge adjustments (895) (976) (1,012) (264) (176) Unit-linked contract income 952 (1,298) 1,183 303 542 Other adjustments (9) (10) (12) — 2 Divested businesses 67 11 — — — Adjusted net investment income $ 21,280 18,189 $ 19,749 $ 4,606 $ 5,068


 
21 Reconciliation of Premiums, Fees and Other Revenues to Adjusted Premiums, Fees and Other Revenues FY23 1Q24 (In millions) Premiums, fees and other revenues $ 51,961 $ 11,975 Less: Adjustments to premiums, fees and other revenues: Asymmetrical and non-economic accounting 29 39 Other adjustments (34) (12) Divested businesses — — Adjusted premiums, fees and other revenues 51,966 $ 11,948


 
22 Expense Detail and Ratios FY23 1Q24 (In millions, except ratio data) Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC Capitalization of DAC $ (2,917) $ (740) Less: Divested businesses — — Adjusted capitalization of DAC $ (2,917) $ (740) Reconciliation of Other Expenses to Adjusted Other Expenses Other expenses $ 12,656 $ 3,191 Less Adjustments to other expenses: Other adjustments 55 7 Divested businesses 38 4 Adjusted other expenses $ 12,563 $ 3,180 Other Detail and Ratios Other expenses, net of capitalization of DAC $ 9,739 $ 2,451 Premiums, fees and other revenues $ 51,961 $ 11,975 Expense ratio 18.7 % 20.5 % Direct expenses $ 5,808 $ 1,426 Less: Total notable items related to direct expenses 96 — Direct expenses, excluding total notable items related to direct expenses $ 5,712 $ 1,426 Adjusted other expenses $ 12,563 $ 3,180 Adjusted capitalization of DAC (2,917) (740) Adjusted other expenses, net of adjusted capitalization of DAC $ 9,646 $ 2,440 Less: Total notable items related to adjusted other expenses 96 — Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses $ 9,550 $ 2,440 Adjusted premiums, fees and other revenues $ 51,966 $ 11,948 Less: PRT 5,324 (25) Adjusted premiums, fees and other revenues, excluding PRT $ 46,642 $ 11,973 Direct expense ratio 11.2 % 11.9 % Direct expense ratio, excluding total notable items related to direct expenses and PRT 12.2 % 11.9 % Adjusted expense ratio 18.6 % 20.4 % Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT 20.5 % 20.4 %